Skip to main content
Frontiers in Cell and Developmental Biology logoLink to Frontiers in Cell and Developmental Biology
. 2026 Nov 2;14:1924507. doi: 10.3389/fcell.2026.1924507

Neuropeptides as neuroimmune modulators in chronic wound healing: mechanistic insights and emerging therapeutic strategies

Jiayi Wu 1,†, Manyan Zhao 1,†, Hongyan Wu 1,†, Xinran Duan 1, Daman Tian 1, Shuangfeng Xu 1, Ting Shi 1, Junfeng Lan 1, Zhifeng Wang 1,*, Jian Wang 1,*, Liwei Xing 1,*
PMCID: PMC13771306  PMID: 43041549

Abstract

Chronic wounds, typified by diabetic foot ulcers, pressure ulcers, and venous leg ulcers, represent a major clinical challenge worldwide. Persistent inflammation associated with disrupted neuroimmune crosstalk is increasingly recognized as an important contributor to impaired chronic wound healing. Neuropeptides, including substance P, calcitonin gene-related peptide, neuropeptide Y, and vasoactive intestinal peptide, act as context-dependent neuroimmune mediators that regulate immune-cell states, inflammation resolution, angiogenesis, re-epithelialization, and extracellular-matrix remodeling through partly distinct mechanisms. This review systematically examines the molecular and cellular mechanisms through which these neuropeptides influence the chronic wound microenvironment, with particular attention to their dose-, phase-, receptor-, and cell-dependent effects. Emerging therapeutic strategies are also summarized, including conventional and stimuli-responsive hydrogels, nanoparticle–hydrogel composites, hydrogel microspheres, microneedles, electrospun scaffolds, cell-based approaches, extracellular-vesicle-based combination strategies, electrical stimulation, photobiomodulation, and anti-infective combination platforms. Most of the available evidence remains preclinical. Key translational challenges include peptide instability, receptor desensitization, wound heterogeneity, delivery-system manufacturing and standardization, and peptide-specific long-term safety. Collectively, current evidence supports neuropeptide signaling as a promising but context-dependent target for precision neuroimmune modulation in chronic wound healing.

Keywords: calcitonin gene-related peptide, chronic wounds, inflammatory reprogramming, neuroimmune regulation, neuropeptide Y, neuropeptides, substance P, vasoactive intestinal peptide

1. Introduction

Chronic wounds are generally defined as wounds that fail to progress through the normal phases of healing within the expected time frame and consequently fail to restore anatomical and functional integrity (Wei et al., 2022; Yuan et al., 2026). Diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PrUs) are representative clinical entities (Armstrong et al., 2023). In contrast to acute wounds, chronic wounds are not simply wounds with delayed closure; rather, they reflect a pathological state characterized by prolonged inflammation, recurrent tissue injury, and dysregulated repair (Morrison et al., 2022). A defining feature is the failure to coordinate the overlapping inflammatory, proliferative, and remodeling programs, resulting in persistent inflammation, insufficient angiogenesis, impaired cell migration, and defective matrix remodeling (Pastar et al., 2023; Wilkinson and Hardman, 2020). The population burden is increasing alongside population aging and the rising prevalence of diabetes, vascular disease, and other chronic disorders (Falanga et al., 2022).

Bioactive peptides and proteins (BPPs) constitute a rapidly expanding therapeutic class for tissue repair because they combine receptor-level specificity, multifunctional microenvironmental regulation, biocompatibility, and biodegradability (Hao et al., 2024). Numerous peptide- and protein-based therapeutics have entered clinical practice across disease areas, with a substantial development pipeline, underscoring the commercial and translational potential of this class (Hao et al., 2024; Muttenthaler et al., 2021). In clinical wound management, becaplermin, a recombinant human platelet-derived growth factor-BB gel, is used as an adjunct to standard care for selected lower-extremity diabetic neuropathic ulcers with adequate perfusion; however, its efficacy has not been established for pressure ulcers or venous stasis ulcers (Smiell et al., 1999). More broadly, topical growth-factor and protein therapies are constrained by proteolytic degradation in chronic wound fluid, short local residence, dose-dependent off-target effects, manufacturing cost, and variable efficacy across wound etiologies (Boeringer et al., 2020; Marti-Carvajal et al., 2015). These limitations motivate the development of smaller bioactive peptides and protective, spatiotemporally controlled delivery systems (Boeringer et al., 2020; Hao et al., 2024).

Neurotrophins are functionally related but molecularly distinct neuroimmune regulators (Botchkarev et al., 2006). Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 signal mainly through Trk receptors and p75NTR to support neuronal survival, axonal growth, reinnervation, and context-dependent immune and vascular responses (Botchkarev et al., 2006; Palazzo et al., 2012). NGF has promoted reparative angiogenesis and reduced endothelial apoptosis in diabetic mouse wounds, illustrating the relevance of neurotrophin signaling to cutaneous repair (Graiani et al., 2004). Compared with these larger proteins, classical neuropeptides such as SP, CGRP, NPY, and VIP are directly released from sensory or autonomic terminals, rapidly couple neural activity to immune and vascular responses, and are generally more amenable to chemical synthesis, sequence modification, and localized delivery (Cheret et al., 2013; Roosterman et al., 2006; Suvas, 2017). Their small size and rapid signaling are advantageous for spatiotemporal modulation, although short half-life, protease sensitivity, receptor desensitization, and dose-dependent pleiotropy remain important limitations (Suvas, 2017; Cheret et al., 2013).

Cutaneous innervation comprises sensory afferents and autonomic efferents with complementary roles. Sensory C and Aδ fibers detect thermal, mechanical, chemical, and inflammatory cues and release SP and CGRP, thereby regulating vascular permeability, leukocyte behavior, keratinocyte activity, and pain (Roosterman et al., 2006; Cheret et al., 2013). Sympathetic fibers release norepinephrine and NPY to influence vascular tone, immune-cell activity, and angiogenesis, whereas parasympathetic/cholinergic signaling is less abundant in skin but may contribute to local anti-inflammatory regulation (Ivanov et al., 2023; Pereira and Leite, 2016). The present review therefore focuses on SP, CGRP, NPY, and VIP because they represent sensory- and autonomic-derived peptide systems with identifiable receptors, direct links to immune and vascular cell crosstalk, and at least some wound-relevant mechanistic or delivery evidence (Al Mamun et al., 2025; Cheret et al., 2013). Other neuronal mediators and candidate neuropeptides are considered separately according to evidence level in Section 3.5 and Table 1.

TABLE 1.

Human neuropeptide sequences, molecular forms, wound-relevant evidence, mechanisms, translational interpretation.

Neuropeptide/human mature sequence Molecular form/principal receptor Evidence level and model Mechanism and wound-relevant effect Translational interpretation Representative references
SP
RPKPQQFFGLM-NH2
Single principal mature SP; TAC1 also produces neurokinin A/NK1R Cell assays; diabetic and full-thickness rodent wounds Stage- and dose-dependent NK1R signaling; immune recruitment, HO-1/NF-κB-linked macrophage responses, fibroblast activity, angiogenesis, and re-epithelialization Rationale supports testing localized, phase-restricted dosing, but this remains provisional; monitor pain, edema, inflammatory amplification, and NK1R desensitization (Leal et al., 2015)
(Kim et al., 2018)
(Zhu et al., 2020)
α-CGRP
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
β-CGRP
ACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAF-NH2
CALCA-encoded α-CGRP; CALCB-encoded β-CGRP; differ at residues 3, 22, 25/CALCRL-RAMP1 Mechanistic mouse injury study; diabetic mouse hydrogel study; no direct α-versus-β chronic-wound head-to-head study identified Limits excess neutrophil accumulation; supports macrophage efferocytosis/reparative states, perfusion, angiogenesis, and matrix deposition Similar receptor pharmacology does not prove wound equivalence; specify isoform, dose, receptor expression, wound stage, and pain/vascular outcomes (Russell et al., 2014; Lu et al., 2024; Li et al., 2025)
NPY1–36
YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2
NPY3–36
DPPIV-cleaved form
Proteolytic forms, not genetic isoforms/Y1R, Y2R, Y5R Endothelial and human-macrophage assays; Y2R-knockout mouse; ischemic rat skin wounds NPY1–36 retains Y1R vasoconstrictor activity; NPY3–36 preferentially activates Y2R (and possibly Y5R), supporting angiogenic signaling; NPY can support p62/NRF2-associated M2-like macrophage responses Measure individual molecular forms; Y1R-dominant vasoconstriction warrants caution in ischemic wounds; wound dosing remains preclinical (Ekstrand et al., 2003; Profumo et al., 2022; Stangerup et al., 2024)
VIP
HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2
Single principal 28-aa mature VIP/VPAC1, VPAC2 Immune/keratinocyte assays; VIP-microsphere nanofiber and rodent wound study cAMP-PKA/CREB signaling restrains NF-κB/AP-1 inflammation, supports IL-10-related responses, keratinocyte repair, VEGF-associated angiogenesis Requires stabilization and local delivery; receptor selectivity, systemic hypotension, and peptide-specific causal evidence require attention (Wang et al., 2016; Dickson and Finlayson, 2009)
NPFF
FLFQPQRF-NH2
NPAF
AGEGLSSPFWSLAAPQRF-NH2
Distinct NPFF-precursor peptides/NPFFR1, NPFFR2 Pain/neuroinflammation pharmacology; no direct cutaneous chronic-wound efficacy study identified Potential modulation of pain–inflammation coupling Hypothesis-generating only; analgesic, inflammatory, and healing endpoints must be tested together (Nguyen et al., 2020)
NPS
SFRNGVGTGMKKTSFQRAKS
Single principal mature NPS/NPSR1 Keratinocyte, fibroblast, endothelial and neural assays; MMP-responsive microneedles in diabetic rodents Supports cell migration, angiogenesis, nerve growth and local inflammatory control in a multifunctional system Promising preclinical candidate; contribution of NPS must be separated from TIMP and carrier effects (Gao et al., 2025)
PACAP-27
HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2
PACAP-38
HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2
Alternative ADCYAP1 precursor-processing products; related to, but not isoforms of, VIP/PAC1, VPAC1, VPAC2 Immune/vascular and skin-response studies; no direct chronic-wound head-to-head comparison cAMP-associated immunoregulation, vasoregulation and cytoprotection; form-dependent stability and tissue potency Potential but not established; migraine/vascular and mast-cell effects require safety evaluation (Toth et al., 2020)
α-MSH
Ac-SYSMEHFRWGKPV-NH2
POMC-derived melanocortin; related melanocortins are not simple α-MSH isoforms/principally MC1R Murine excisional wounds; human burns/scars localization; fibroblast assays Anti-inflammatory and antifibrotic signaling; can alter leukocyte recruitment, collagen production and scar remodeling Direct chronic-ulcer evidence is lacking; dose and timing may shift inflammation or fibrosis (Muffley et al., 2011; de Souza et al., 2015)
Somatostatin-14
AGCKNFFWKTFTSC
Somatostatin-28
SANSNPAMAPRERKAGCKNFFWKTFTSC
Alternative precursor-processing products/SSTR1–SSTR5 General anti-inflammatory, endocrine and vascular pharmacology; direct chronic-wound efficacy not established Potential restraint of inflammatory and secretory activity; tissue distribution and receptor kinetics differ by form Hypothesis-generating; wound-specific receptor mapping and direct efficacy studies are required (Olias et al., 2004)
Galanin
GWTLNSAGYLLGPHAIDNHRSFSDKHGLT
Galanin; GALP and alarin are separate family peptides, not galanin isoforms/GALR1–GALR3 Skin expression and inflammation/cell-proliferation literature; limited direct chronic-wound evidence Potential regulation of cutaneous inflammation, nociception and cellular proliferation Requires peptide- and receptor-specific wound studies; avoid assuming family members are interchangeable (Bauer et al., 2008)
Oxytocin
CYIQNCPLG-NH2
Single principal mature peptide/OXTR Systemic stress, immune and repair-related literature; no direct chronic-wound efficacy study identified Possible indirect immunoregulatory and stress-axis effects Hypothesis-generating; direct chronic-wound efficacy and wound-specific OXTR mapping remain to be established (Viero et al., 2010)

Abbreviations: aa, amino acid(s); α-CGRP, alpha-calcitonin gene-related peptide; β-CGRP, beta-calcitonin gene-related peptide; AP-1, activator protein 1; cAMP, cyclic adenosine monophosphate; CALCA, calcitonin-related polypeptide alpha gene; CALCB, calcitonin-related polypeptide beta gene; CALCRL, calcitonin receptor-like receptor; CREB, cAMP, response element-binding protein; DPPIV/CD26, dipeptidyl peptidase IV/cluster of differentiation 26; GALP, galanin-like peptide; GALR1–GALR3, galanin receptors 1–3; HO-1, heme oxygenase 1; IL-10, interleukin 10; MC1R, melanocortin 1 receptor; MMP, matrix metalloproteinase; NF-κB, nuclear factor kappa B; NK1R, neurokinin 1 receptor; NPAF, neuropeptide AF; NPFF, neuropeptide FF; NPFFR1/2, neuropeptide FF, receptors 1 and 2; NPS, neuropeptide S; NPSR1, neuropeptide S receptor 1; NPY, neuropeptide Y; NRF2, nuclear factor erythroid 2-related factor 2; p62, sequestosome 1; OXTR, oxytocin receptor; PAC1, pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PKA, protein kinase A; POMC, proopiomelanocortin; RAMP1, receptor activity-modifying protein 1; SP, substance P; SSTR1–SSTR5, somatostatin receptors 1–5; TAC1, tachykinin precursor 1; TIMP, tissue inhibitor of metalloproteinases; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide; VPAC1/2, vasoactive intestinal peptide receptors 1 and 2; Y1R/Y2R/Y5R, neuropeptide Y receptors Y1, Y2 and Y5; α-MSH, alpha-melanocyte-stimulating hormone.

With increasing recognition of the ability of neuropeptides to remodel the neuroimmune microenvironment and promote the shift from chronic inflammation toward repair, neuroimmune dysregulation has emerged as a key driver of persistent inflammation and insufficient regeneration in chronic wounds (Nardini and Bacci, 2025). As the largest organ of the body, the skin is integrated within a neuroendocrine-immune-cutaneous network that maintains tissue homeostasis and coordinates repair after injury (Xing et al., 2024). Following acute skin injury, sensory nerve terminals release multiple neuropeptides, including substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and neuropeptide Y (NPY).

These mediators regulate vascular tone, immune cell recruitment, inflammation resolution, keratinocyte migration, fibroblast activation, and extracellular matrix remodeling, thereby supporting orderly wound healing (Palomeque Chavez et al., 2026). In chronic wounds, particularly DFUs, persistent inflammation, metabolic stress, and local ischemia can damage peripheral sensory nerve endings, impair wound reinnervation, and disrupt beneficial interactions along the skin–nerve axis. Because SP, CGRP, VIP, and NPY are largely supplied by intact or regenerating peripheral nerve fibers, structural nerve damage may compromise local neuropeptide signaling. Moreover, emerging evidence suggests Schwann cells normally provide trophic support, regulate extracellular-matrix remodeling, and adopt repair-associated states after peripheral-nerve injury; diabetes and sustained metabolic stress can impair these functions and thereby hinder axonal regeneration and reinnervation (Oliveira et al., 2023; Nowak et al., 2021; Sango et al., 2017). Together, impaired nerve regeneration and reduced neuropeptide availability further compromise neurogenic immune regulation, angiogenesis, and tissue remodeling (Oliveira et al., 2023; Cheret et al., 2013; Roosterman et al., 2006).

Based on these considerations, this review summarizes recent advances in the mechanisms by which neuropeptides regulate chronic wound healing, focusing on the roles of SP, CGRP, VIP, and NPY in immune modulation, inflammation resolution, angiogenesis, cell migration, and tissue remodeling. The review also discusses neuropeptide-based intelligent delivery platforms and combinatorial therapeutic strategies. By integrating interactions among neuropeptides, immune cells, peripheral nerve structures, and the wound microenvironment, this review provides a mechanistic foundation for the development of neuropeptide-based therapies for chronic wounds and outlines future research directions in this field.

2. Pathological features of chronic wounds: neuroimmune dysregulation as a driver of prolonged inflammation

Physiological wound healing is a highly coordinated and dynamic process conventionally described as hemostasis, inflammation, proliferation, and remodeling (Knoedler et al., 2023). These phases are not discrete or strictly sequential; instead, they overlap in time and are linked by reciprocal interactions among immune cells, vascular cells, keratinocytes, fibroblasts, peripheral nerves, and extracellular-matrix components (Landen et al., 2016). During effective repair, neutrophil-dominated antimicrobial defense is followed by the clearance of inflammatory cells and a gradual shift of macrophages from predominantly pro-inflammatory states toward heterogeneous pro-resolving and reparative phenotypes (Landen et al., 2016; Krzyszczyk et al., 2018). These coordinated transitions support growth-factor production, fibroblast activity, angiogenesis, re-epithelialization, and matrix remodeling (Krzyszczyk et al., 2018). Chronic wounds, by contrast, fail to restore anatomical and functional integrity within the expected healing period through an orderly repair program (Powers et al., 2016). Their central pathological feature is not the persistence of a single phase, but a failure to coordinate overlapping inflammatory and reparative processes, resulting in sustained proteolysis, impaired angiogenesis, defective cell migration, and inadequate matrix reconstruction (Pastar et al., 2023). Systemic disorders, including venous or arterial insufficiency, diabetes, and diabetes-associated neuropathy, provide the broader pathological context, whereas local neuroimmune dysregulation contributes to the loss of wound-microenvironment homeostasis and the failure to initiate effective healing (Raziyeva et al., 2021).

In chronic wounds, neuroimmune dysregulation spans metabolic stress, peripheral-nerve dysfunction, and impaired intercellular signaling. Hyperglycemia, ischemia, and oxidative stress can disturb mitochondrial function and endoplasmic-reticulum homeostasis in peripheral neurons and supporting cells, thereby reducing cellular bioenergetic capacity and increasing susceptibility to axonal injury (Nowak et al., 2021; Sango et al., 2017). Oxidative stress has also been shown to inhibit microtubule-dependent axonal transport before overt axonal degeneration becomes detectable (Fang et al., 2012). Because the delivery of neuropeptide-containing vesicles to peripheral nerve terminals depends on energy-requiring axonal transport, these abnormalities provide a plausible mechanism for reduced local neuropeptide availability (Maday et al., 2014). Mitochondria-associated endoplasmic-reticulum membranes may participate in this process by regulating calcium transfer and bioenergetic homeostasis (Paillusson et al., 2016).

Persistent inflammation and oxidative stress can further damage cutaneous sensory and autonomic nerve fibers, reduce the expression or release of neuropeptides such as SP and CGRP, and weaken bidirectional communication between neural and immune cells (Pradhan et al., 2009; Theocharidis and Veves, 2020). Loss of this regulatory input can impair immune-cell recruitment and resolution, vascular responses, and stromal-cell activity (Cheret et al., 2013). Receptor-level dysfunction may further attenuate the remaining signal. For example, sustained SP exposure can promote GRK-mediated phosphorylation and β-arrestin-dependent internalization of NK1R, thereby reducing cell-surface receptor availability and downstream responsiveness (McConalogue et al., 1998; Moore et al., 2007). This example illustrates how persistent stimulation may convert an initially adaptive neuroimmune signal into a desensitized state; the peptide-specific cellular pathways are discussed in Section 3(Moore et al., 2007; McConalogue et al., 1998).

Taken together, sustained metabolic disturbance, neural dysfunction, and attenuated neuropeptide signaling collectively disrupt the neuroimmune regulatory network in chronic wounds. As neural control over immune-cell inflammatory responses declines, the persistently activated inflammatory microenvironment further exacerbates nerve injury. This may establish a self-reinforcing cycle between neural damage and immune imbalance, potentially maintaining the wound in a prolonged inflammatory state and preventing progression into proliferation and remodeling, ultimately contributing to chronic nonhealing (Figure 1).

FIGURE 1.

Infographic illustrating neuroimmune dysregulation in chronic wound healing shows hyperglycemia, ischemia, oxidative stress, and infection causing nerve dysfunction and dysregulated neuropeptide signaling, leading to impaired wound responses, persistent inflammation, impaired angiogenesis, defective re-epithelialization, and impaired extracellular matrix remodeling, resulting in chronic nonhealing wounds.

Neuroimmune dysregulation in chronic wound healing. Chronic wound-associated factors, including hyperglycemia, ischemia/hypoxia, oxidative stress, and infection/biofilm, contribute to peripheral nerve and Schwann-cell dysfunction, impaired axonal transport, and dysregulated neuropeptide signaling, including altered availability of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and vasoactive intestinal peptide (VIP). Physiological wound healing depends on overlapping and coordinated cellular and tissue responses involving neutrophils, macrophages, endothelial cells, keratinocytes, fibroblasts, peripheral nerves, and the extracellular matrix (ECM), which collectively support inflammatory resolution, angiogenesis, re-epithelialization, reinnervation, and ECM remodeling. Disruption of neuropeptide signaling may impair these coordinated responses, contributing to persistent inflammation, defective angiogenesis and re-epithelialization, sustained proteolysis, and impaired ECM remodeling, ultimately promoting chronic wound-healing arrest. In turn, persistent inflammation, reactive oxygen species (ROS), and proteases can further aggravate peripheral nerve damage, while dysregulated neuropeptide signaling further impairs wound healing, forming a self-reinforcing neuroimmune cycle that favors chronic nonhealing wounds. Abbreviations: CGRP, calcitonin gene-related peptide; ECM, extracellular matrix; NPY, neuropeptide Y; ROS, reactive oxygen species; SP, substance P; VIP, vasoactive intestinal peptide. Created in BioRender. https://BioRender.com/hiag5vt.

3. Neuropeptides as neuroimmune modulators in chronic wound healing

Impaired chronic wound healing results from the combined effects of disrupted innervation, insufficient neuropeptide availability, persistent inflammation, impaired angiogenesis, and aberrant extracellular matrix remodeling. Neuropeptides are not merely paracrine factors released by nerve terminals; rather, they serve as important mediators linking neural, immune, vascular, and cutaneous cellular components within the wound microenvironment. SP, CGRP, NPY, and VIP participate in inflammatory regulation, vascular regeneration, re-epithelialization, and matrix remodeling through distinct receptor systems and target cells. Their major characteristics are summarized in Table 1.

3.1. Substance P: spatiotemporal control from inflammatory initiation to reparative remodeling

Substance P (SP), an 11-amino-acid tachykinin neuropeptide encoded by tachykinin precursor 1 (TAC1), is an important mediator within the cutaneous neuroimmune network (Xing et al., 2024). It is primarily stored in unmyelinated C fibers and a subset of Aδ sensory fibers and is rapidly released into the local microenvironment after tissue injury or inflammatory stimulation (Beraud et al., 2022). Beyond neuronal sources, immune cells, including macrophages and monocytes, can also express SP and its high-affinity receptor, the neurokinin-1 receptor (NK1R) (Mostek-Majewska et al., 2021). Structural studies of antagonist-bound human NK1R have provided important insight into ligand recognition and receptor selectivity (Singla et al., 2017).Upon binding to NK1R, SP activates Gq/11-coupled signaling cascades and regulates downstream transcriptional programs associated with inflammation and repair (Beraud et al., 2022; Espina et al., 2021). Together, the broad cellular distribution of NK1R and its well-defined ligand-recognition mechanism support the role of SP as an important mediator of neuroimmune communication (Espina et al., 2021; Gao et al., 2024) (Figure 2A).

FIGURE 2.

Four-panel scientific diagram explaining neuropeptide control in wound healing and inflammation. Panel A shows substance P signaling and impaired response in diabetic wounds. Panel B presents CGRP’s role in resolving inflammation via macrophage behavior modulation and angiogenesis. Panel C details NPY’s dual receptor pathways switching macrophage polarization, with persistent inflammation under diabetic conditions. Panel D describes VIP’s anti-inflammatory and reparative effects through immune cell signaling and keratinocyte activation.

Neuropeptide-specific mechanisms regulating neuroimmune responses during chronic wound healing. (A) Substance P (SP) released primarily from C/Aδ sensory fibers signals through the neurokinin-1 receptor (NK1R) and exerts context- and phase-dependent effects. Early SP signaling contributes to vasodilation, inflammatory-cell recruitment, and NF-κB-associated inflammatory responses, whereas later repair-associated signaling involving HO-1 may favor reparative macrophage states, collagen deposition, and angiogenesis. Reduced SP availability in diabetic wounds may contribute to persistent inflammation. (B) Calcitonin gene-related peptide (CGRP) released from sensory nerve endings acts through the CALCRL-RAMP1 receptor complex. CGRP-RAMP1 signaling and downstream TSP-1-associated responses can limit excessive neutrophil recruitment, enhance macrophage efferocytosis, reduce DAMP-associated inflammatory amplification, and favor inflammation resolution and reparative macrophage transition. CGRP also supports angiogenesis, vascular maturation, and organized collagen deposition. (C) Neuropeptide Y (NPY) is predominantly released from perivascular sympathetic nerve fibers. Full-length NPY1-36 can signal through Y1R, whereas cleavage by dipeptidyl peptidase IV (DPPIV/CD26) generates NPY3-36 with preferential Y2R-associated activity, supporting VEGF- and NO-related angiogenic responses. NPY may additionally modulate macrophage inflammatory and oxidative-stress responses through p38 MAPK/NF-κB- and p62/SQSTM1-NRF2/HO-1-associated pathways. (D) Vasoactive intestinal peptide (VIP) acts through VPAC1 and VPAC2 receptors to activate cAMP-PKA/CREB signaling. VIP may suppress TLR/NF-κB-associated pro-inflammatory responses, enhance IL-10-related signaling, favor reparative macrophage states and regulatory immune responses, and promote keratinocyte-mediated re-epithelialization and VEGF-associated angiogenic support. Together, these pathways illustrate the distinct but complementary mechanisms through which SP, CGRP, NPY, and VIP may regulate inflammation resolution and tissue repair in chronic wounds. Abbreviations: CALCRL, calcitonin receptor-like receptor; CGRP, calcitonin gene-related peptide; DAMPs, damage-associated molecular patterns; DPPIV/CD26, dipeptidyl peptidase IV/cluster of differentiation 26; HO-1, heme oxygenase-1; NF-κB, nuclear factor kappa B; NK1R, neurokinin-1 receptor; NO, nitric oxide; NPY, neuropeptide Y; NRF2, nuclear factor erythroid 2-related factor 2; PKA, protein kinase A; RAMP1, receptor activity-modifying protein 1; SP, substance P; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide; VPAC1/2, vasoactive intestinal peptide receptors 1 and 2. Created in BioRender. https://BioRender.com/kti5xuo.

SP is increasingly recognized as a neuroimmune modulator with strong spatiotemporal context dependence. During the early phase of acute injury, SP promotes vasodilation and immune-cell recruitment, thereby supporting the rapid establishment of an innate immune response. As repair proceeds, SP contributes to fibroblast migration, collagen deposition, and angiogenesis, facilitating the transition from inflammation toward tissue regeneration (Redkiewicz, 2022; Zaarour et al., 2022). Thus, the central role of SP in wound healing is not simply pro-inflammatory or pro-reparative, rather, it depends on the timing, local concentration, receptor availability, and inflammatory status of the tissue microenvironment.

SP may influence the disrupted inflammatory trajectory of diabetic wounds and reprogram macrophage function through signaling involving HO-1/NF-κB axis (Zaarour et al., 2022; Montana and Lampiasi, 2016). In diabetic chronic wounds, persistent hyperglycemia and peripheral neuropathy may reduce local SP availability, alter macrophage phenotypic transitions, and contribute to persistent inflammation. Mechanistic studies have shown that SP can reshape macrophage behavior at the molecular level (Leal et al., 2015). In RAW264.7 macrophages, SP promotes reparative macrophage phenotype by upregulating heme oxygenase-1 (HO-1), a key cytoprotective and anti-inflammatory enzyme regulated by the SP-NK1R axis (Montana and Lampiasi, 2016; Lim et al., 2017). This provides mechanistic support for the ability of SP to correct the macrophage homeostasis in diabetic wounds (Lim et al., 2017). At the same time, SP can activate NF-κB signaling and induce selected cytokine programs in the monocyte-macrophage lineage. Thus, SP may initiate necessary inflammatory defense through NF-κB during early injury, while facilitating inflammation resolution and reparative polarization through HO-1-mediated negative feedback during later or chronic phases, underscoring its bidirectional immunomodulatory capacity (Ziche et al., 1990; Bardelli et al., 2005).

In vivo, Maranha et al. reported in a diabetic mouse wound model that local SP supplementation modulated inflammatory and reparative responses in a diabetic mouse wound model. SP treatment enhanced early inflammatory-cell recruitment, followed by timely resolution of inflammation restoration, increased M2-like macrophage abundance, increased α-SMA-positive myofibroblasts, and enhanced CD31-positive neovascularization (Maranha et al., 2026; Um et al., 2016). Collectively, in vitro and in vivo findings suggest that SP does not merely suppress inflammation. Instead, it helps restore the temporal organization of inflammation in diabetic wounds through molecular pathways including inflammatory and macrophage-regulatory signaling axes, enabling macrophage responses to proceed through initiation, amplification, and resolution in a coordinated manner (Leal et al., 2015; Maranha et al., 2026).

Importantly, the role of SP in wound healing is not fixed and is likely influenced by its local concentration, duration of exposure, receptor availability, and the inflammatory state of the wound. These variables, however, have not yet been systematically compared in chronic cutaneous wounds. During the early stage of injury, SP can initiate an acute inflammatory response, influence macrophage activity, and promote the mobilization or functional recovery of stromal cells involved in tissue repair (Park et al., 2016; Hong et al., 2009; Suvas, 2017). This early response may help establish the conditions required for subsequent healing. The situation may be different when SP–NK1R signaling persists. Evidence from other inflammatory settings indicates that prolonged signaling may increase vascular permeability, leukocyte recruitment, pain sensitization, NF-κB activation, and reactive oxygen species production (Johnson et al., 2016; Zieglgansberger, 2019). Whether all these effects occur together in chronic skin wounds is still uncertain. Excessive neutrophil accumulation and NET formation can independently increase the local protease burden, aggravate tissue damage, and delay wound healing (Heuer et al., 2021; Zhu et al., 2021). Nevertheless, there is currently insufficient evidence to conclude that SP directly induces pathological NET formation in chronic wounds. SP should therefore not be viewed as invariably beneficial to healing. Its overall effect is more likely to vary with the wound stage, local peptide availability, NK1R expression, proteolytic activity, and the existing inflammatory burden (Suvas, 2017).

Another feature that needs to be considered is the agonist-induced internalization and desensitization of NK1R. After SP binds to the full-length receptor, NK1R may undergo GRK-mediated phosphorylation, recruit β-arrestin, and subsequently enter the cell through receptor endocytosis (McConalogue et al., 1998). This process can reduce the cellular response to repeated stimulation, although receptor internalization does not simply mean that all downstream signaling stops. Some signaling activity may continue from intracellular compartments (Steinhoff et al., 2014). For this reason, prolonged exposure to exogenous SP could change receptor responsiveness rather than maintain a stable reparative signal. At present, however, there is little direct evidence showing that continuous SP administration is less effective than intermittent administration in chronic cutaneous wounds. Localized and dose-controlled delivery may be worth exploring, but it should be regarded as a therapeutic hypothesis rather than an established treatment principle (Redkiewicz, 2022).

Taken together, current evidence indicates that SP is involved in the early inflammatory response after injury and may also contribute to the later transition from inflammation to tissue repair. Its biological effect nevertheless depends heavily on the cellular environment and the intensity of local inflammation (Mashaghi et al., 2016; Park et al., 2016). At the molecular level, activation of full-length NK1R can stimulate Gq/11-dependent Ca2+ mobilization and activate PKC and MAPK/ERK signaling. Under particular experimental conditions, the same receptor system may also promote NF-κB-dependent inflammatory responses (Steinhoff et al., 2014; Garcia-Recio and Gascon, 2015). Future SP-based therapies may therefore need more than simple peptide supplementation. A more practical direction would be to regulate where, when, and to what extent SP–NK1R signaling is activated, so that repair-supportive activity is retained without unnecessarily increasing vascular leakage, pain sensitization, persistent inflammation, or neutrophil- and NET-associated tissue injury. This phase-oriented treatment concept remains provisional and will require direct testing in chronic-wound models, followed by validation in well-designed clinical studies.

3.2. CGRP: a neuroimmune bridge linking inflammation resolution to reparative activation

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide abundantly expressed in sensory neurons and represents a major peptide mediator released from sensory nerve terminals. It is predominantly synthesized and stored in Nav1.8+ nociceptors and is rapidly released into the local microenvironment upon tissue injury or inflammatory stimulation (Russell et al., 2014; Lu et al., 2024). CGRP is a key mediator of neurogenic inflammation and vascular responses, and, in chronic wound healing, may serve as a functional link between neural sensing, immune restraint, and tissue regeneration (Choi and Di Nardo, 2018). CGRP signals through a receptor complex composed of calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein 1 (RAMP1), with RAMP1 being essential for high-affinity ligand recognition (Cao et al., 2024; Lu et al., 2024; Booe et al., 2015). This defined receptor architecture and relatively specific tissue distribution support the role of CGRP in neuroimmune regulation. In chronic wounds, particularly DFUs and pressure injuries, peripheral neuropathy, sensory nerve terminal degeneration (Dasari et al., 2021), and insufficient local neuropeptide release can markedly reduce CGRP bioavailability, thereby contributing to persistent inflammatory arrest (Russell et al., 2014; McLatchie et al., 1998; Nowak et al., 2021) (Figure 2B).

Human CGRP comprises two 37-amino-acid isoforms encoded by separate genes. α-CGRP is encoded by CALCA and predominates in cutaneous sensory neurons, whereas β-CGRP is encoded by CALCB and is relatively enriched in enteric neurons (Russell et al., 2014; Nikas et al., 1986). The mature peptides differ at residues 3, 22, and 25 but share the N-terminal disulfide loop and amidated C-terminus required for receptor activation (Russell et al., 2014; Atci et al., 2017). Both can activate the canonical CALCRL-RAMP1 CGRP receptor and generally show similar high potency in standard pharmacological assays; however, similarity in receptor pharmacology should not be interpreted as proven equivalence in chronic wounds (Atci et al., 2017; Blufpand et al., 2013). To date, available studies investigating CGRP in chronic wound healing have generally reported total CGRP levels or focused predominantly on α-CGRP, whereas direct comparisons between α-CGRP and β-CGRP in diabetic foot ulcers, venous leg ulcers, pressure injuries, or related chronic wound models remain limited. Most wound studies report only “CGRP” or use α-CGRP without testing β-CGRP (Patel and Bihani, 2018; Bailey et al., 2010). Therefore, the available evidence supports overlapping receptor activity but does not establish that the two isoforms have indistinguishable effects on inflammation resolution, angiogenesis, pain, or matrix remodeling in chronic wounds. Future studies should report the isoform, dose, receptor occupancy, and wound stage explicitly (Patel and Bihani, 2018; Wee et al., 2003).

The CGRP-RAMP1-TSP-1 axis may represent a key mechanism by which CGRP reprograms myeloid-cell function (Kulalert et al., 2024). Upon engagement of its receptor complex, CGRP can upregulate thrombospondin-1 (TSP-1), thereby modulating neutrophil and macrophage migration, survival, phagocytosis, and polarization (Liu et al., 2025). Studies have shown that TSP-1 is among the genes markedly induced in neutrophils and macrophages following CGRP stimulation, potentially amplifying CGRP-driven reparative effects through autocrine or paracrine signaling. Pharmacological blockade of CGRP signaling with the receptor antagonist BIBN4096 further supports the relevance of this pathway, as CGRP inhibition delays wound healing, reduces collagen deposition, impairs epithelial regeneration, and limits macrophage transition toward reparative states. (Liu et al., 2025). Consistently, TSP-1 deficiency attenuates or abolishes CGRP-mediated regulation of myeloid-cell migration, cell death, phagocytosis, and polarization, indicating that the RAMP1-TSP-1 axis is an important downstream route through which CGRP coordinates myeloid-cell remodeling and wound healing.

CGRP regulates myeloid-cell behavior primarily by limiting excessive recruitment, promoting apoptotic-cell clearance, and enhancing phagocytic capacity. In neutrophils, CGRP can restrain excessive recruitment to sites of injury and, in the presence of pro-inflammatory mediators such as IL-1β and tumor necrosis factor-alpha (TNF), accelerate neutrophil death, thereby preventing sustained accumulation of inflammatory cells (Lu et al., 2024). In macrophages, CGRP not only influences recruitment but also enhances efferocytosis, the clearance of apoptotic neutrophils and dying inflammatory cells. This process is essential for timely termination of inflammation. In chronic wounds, nonhealing is not simply the result of inadequate inflammation; rather, it is more often driven by persistent inflammation that fails to resolve. By enhancing macrophage efferocytosis (Zhang et al., 2024), CGRP may reduce secondary necrosis, limit the release of damage-associated molecular patterns (DAMPs), and dampen the amplification of inflammatory cascades, creating a microenvironment more conducive to granulation tissue formation, angiogenesis, and re-epithelialization (Dasari et al., 2021; Khanna et al., 2010). Accordingly, the CGRP-RAMP1 axis can be viewed as a neuroimmune pathway linking inflammation resolution to reparative transition (Lu et al., 2024).

Beyond immunomodulation, CGRP may also facilitate the transition from inflammation to proliferation by regulating angiogenesis and matrix remodeling (Russell et al., 2014). As a potent vasodilatory peptide, CGRP can improve local perfusion and, in some contexts, enhance flap survival. In diabetic mouse wound models, reduced CGRP levels are accompanied by decreased CD31 and α-SMA expression, suggesting a potential role in neovessel formation and vascular maturation (Russell et al., 2014; Lim et al., 2017). CD31 reflects endothelial abundance and angiogenic activity, whereas α-SMA is associated with vascular smooth muscle cell recruitment and vessel stabilization (Lertkiatmongkol et al., 2016; Song et al., 2020); together, these markers indicate the quality of vascular network formation within the wound bed. CGRP also appears to influence collagen metabolism: CGRP deficiency prolongs wound healing and reduces collagen deposition, whereas CGRP supplementation may promote fibroblast organization and orderly collagen fiber deposition, supporting recovery of wound tensile strength (Liu et al., 2025). These vascular and matrix effects may act in concert with immune-cell remodeling to drive chronic wounds toward coordinated repair (Li et al., 2025).

Notably, the effect of CGRP on efferocytosis is highly tissue-context dependent. In endometriosis, CGRP/RAMP1 signaling in macrophages has been reported to inhibit efferocytosis and potentially promote lesion growth, which contrasts with its efferocytosis-enhancing and inflammation-resolving role in cutaneous wound healing (Fattori et al., 2024; Russell et al., 2014). This discrepancy indicates that CGRP biology is not fixed, but is shaped by tissue context, inflammatory status, cellular composition, and local co-stimulatory cues. Therefore, the reparative role of CGRP should be interpreted within its specific microenvironmental context, rather than being simplified as uniformly anti-inflammatory or pro-healing.

Overall, CGRP appears to regulate myeloid-cell function in chronic wounds largely through pathways such as RAMP1-TSP-1, while also interacting with angiogenesis and matrix remodeling to promote the transition from persistent inflammation to repair. Importantly, CGRP activity is influenced by tissue type, inflammatory intensity, and injury phase. Future studies should further define its therapeutic window, context-specific functions, and regulatory limits across distinct chronic wound settings (Fattori et al., 2024; Li et al., 2025).

3.3. NPY: a bidirectional modulator of neurovascular and immunometabolic remodeling

Neuropeptide Y (NPY) is a highly conserved 36-amino-acid neuropeptide broadly expressed in the central and peripheral nervous systems (Anderson et al., 2022; Xing et al., 2024). In the skin, NPY is predominantly released from perivascular sympathetic nerve terminals, often together with norepinephrine (Li and Deng, 2008). Under specific microenvironmental conditions, endothelial cells, macrophages, and adipose tissue-associated cells may also contribute to local NPY signaling networks (de Lusignan et al., 2021). NPY acts mainly through G protein-coupled Y receptors, including Y1R, Y2R, Y4R, and Y5R, among which Y1R, Y2R, and Y5R are most closely related to cutaneous vascular responses, inflammation, and wound healing (Grant and Zukowska, 2000; Wultsch et al., 2006). These receptors are primarily coupled to Gi/o proteins, leading to inhibition of adenylyl cyclase, reduced intracellular cAMP, and regulation of downstream pathways such as MAPK/ERK, PI3K-AKT, p38 MAPK, NF-κB, and ion channel-associated signaling through Gβγ subunits (Friston, 1998). Because Y receptor expression varies across endothelial cells, vascular smooth muscle cells, macrophages, and fibroblasts, NPY exerts cell-type-specific and phase-dependent effects within the wound microenvironment (Xing et al., 2024; Al Mamun et al., 2025). (Figure 2C)

One particularly relevant function of NPY in chronic wounds is its capacity to promote angiogenesis under ischemic conditions (Lee et al., 2003). NPY1–36 and NPY3–36 should be described as proteolytic molecular forms rather than genetically encoded isoforms: endothelial dipeptidyl peptidase IV (DPPIV/CD26) removes the two N-terminal residues of NPY1–36 to generate NPY3–36 (Willer et al., 1993). This processing produces a biologically meaningful receptor switch. Full-length NPY retains high activity at Y1R and can contribute to vasoconstriction, whereas NPY3–36 exhibits reduced Y1R activity but preferentially activates Y2R (and possibly Y5R), thereby promoting endothelial migration, proliferation, and angiogenic responses through mechanisms involving VEGF and nitric oxide signaling (Willer et al., 1993; Wahlestedt et al., 1986; Hauser et al., 1998). Y2R deletion reduces NPY-induced angiogenesis and delays cutaneous wound healing. However, whether locally generated NPY3–36 contributes to these effects in vivo remains unclear, as most wound studies have not directly quantified NPY processing products (Lubics et al., 2003). Thus, unlike the unresolved α/β-CGRP comparison, NPY processing forms have demonstrably different receptor preferences and potentially different vascular consequences. Future wound studies should consider assessing NPY1–36 and NPY3–36 separately, rather than assuming that total NPY levels fully reflect NPY signaling activity in the wound microenvironment.

Beyond angiogenesis, NPY may also relieve inflammatory arrest in chronic wounds by modulating macrophage phenotypic switching. Chronic wounds such as DFUs are exposed to hyperglycemia, hypoxia, advanced glycation end products, bacterial biofilms, and sustained ROS, all of which can maintain macrophages in an pro-inflammatory macrophage state. This state is characterized by persistent elevation of TNF-α, IL-1β, IL-6, IL-12, inducible nitric oxide synthase (iNOS), and matrix metalloproteinases (MMPs), leading to extracellular matrix degradation and impaired migration of endothelial cells and keratinocytes (Wang Q. et al., 2025; Profumo et al., 2022). Studies have reported that NPY can attenuate lipopolysaccharide (LPS)- or interferon-gamma (IFN-γ)/LPS-induced inflammatory responses, suppress TNF-α and IL-12 expression, and reduce antigen-presentation markers such as HLA-DR. At the same time, NPY can increase markers associated with reparative macrophage states, including CD163, CD206, and IL-10, thereby enhancing macrophage-mediated clearance and inflammation resolution (Profumo et al., 2022). These findings suggest that NPY is not simply an anti-inflammatory peptide; rather, it may reprogram macrophage function and shift wound inflammation from destructive persistence toward regulated clearance and repair.

At the molecular level, the macrophage-modulatory effects of NPY may be mediated, at least in part, by Y1R-linked inflammatory signaling, p38 MAPK/NF-κB-related pathways, p62/SQSTM1-dependent autophagy, and activation of the NRF2/HO-1 antioxidant axis. In chronic wounds, persistent NF-κB activation drives the expression of inflammatory mediators such as TNF-α, IL-1β, and IL-6, thereby maintaining the wound in a prolonged inflammatory phase (Profumo et al., 2022; Zhu et al., 2025). Through the Y receptor-mediated Gi/o signaling, NPY may interfere with p38 MAPK and NF-κB activation, reducing inflammatory mediator release and attenuating pro-inflammatory macrophage responses (Pradhan et al., 2009). NPY may also promote autophagy-associated molecules, including LC3-II and p62/SQSTM1, thereby enhancing macrophage clearance of damaged organelles, oxidized lipids, and inflammatory stimuli. As both an autophagy adaptor and a regulator of NRF2 activation, p62/SQSTM1 can facilitate NRF2 release and nuclear translocation (Pradhan et al., 2009). Nuclear NRF2 then induces antioxidant genes such as HO-1, lowers the ROS burden, and further restrains NF-κB-driven inflammatory amplification. Through this sequence-autophagy enhancement, NRF2/HO-1 activation, ROS reduction, and NF-κB inhibition-NPY may help interrupt the self-amplifying cycle of oxidative stress and inflammation in chronic wounds.

A further notable feature of NPY in chronic wound healing is its biphasic and receptor-switching nature. Depending on concentration, receptor distribution, and disease phase, the same NPY molecule may exert distinct or even opposing effects. During early injury or at high local concentrations, Y1R-related signaling may enhance vasoconstriction or inflammatory responses, potentially compromising perfusion in ischemic wounds (Damon, 2008). In contrast, ischemia-induced DPPIV expression can process NPY into a form that preferentially engages Y2R/Y5R, thereby favoring endothelial migration, angiogenesis, and tissue repair. Thus, the therapeutic value of NPY should not be framed as simple peptide replacement, but as precise spatiotemporal control of NPY signaling (Kuo et al., 2007). Future neuropeptide-based strategies may focus on selectively activating the pro-angiogenic NPY-Y2/Y5-DPPIV-VEGF/eNOS/NO axis, coordinately modulating the NPY-Y1R/p38 MAPK/NF-κB inflammatory inhibitory axis, and engaging the NPY-p62/SQSTM1-NRF2/HO-1 axis to restore antioxidant and immunometabolic homeostasis in chronic wounds (Sigorski et al., 2025).

3.4. VIP: a neuroimmune peptide governing inflammation resolution and the reparative transition in chronic wounds

Vasoactive intestinal peptide (VIP) is a highly basic 28-amino-acid peptide that is broadly distributed in the central, peripheral, and enteric nervous systems, as well as in the respiratory tract, pancreas, cardiovascular system, and cutaneous nerve fibers (Fahrenkrug, 1979; Al Mamun et al., 2025). Beyond neuronal sources, VIP can participate in local paracrine regulation within immune cell-associated microenvironments (Ganea et al., 2015). Thus, VIP should not be viewed merely as a vasodilatory peptide, but rather as a neuroimmune mediator linking nerve terminals, immune cells, epithelial cells, and vascular endothelial cells. In chronic wounds, VIP is particularly relevant for restraining excessive inflammation, promoting immune tolerance, improving epithelial repair, and supporting angiogenesis (Yu et al., 2010) (Figure 2D).

VIP primarily signals through two high-affinity receptors, VPAC1 and VPAC2, both of which are class B G protein-coupled receptors (Tanaka et al., 2023). VPAC1 is broadly expressed in immune and epithelial cells and is commonly involved in basal immune regulation, whereas VPAC2 expression may be upregulated in certain cell types during inflammatory stimulation or tissue injury. Upon binding to VPAC1/VPAC2, VIP activates Gs proteins, stimulates adenylyl cyclase, increases intracellular cAMP, and engages downstream PKA, EPAC, and CREB signaling. Depending on the target cell and receptor context, VIP may also activate ERK/MAPK signaling. The VPAC-cAMP-PKA/CREB axis therefore represents a central pathway underlying the anti-inflammatory and repair-modulatory actions of VIP(Nishimoto et al., 2011; Dickson and Finlayson, 2009; Chagnon-Lessard et al., 2026).

Chronic wounds remain trapped in the inflammatory phase not because inflammation is insufficient, but because it fails to terminate appropriately. VIP is particularly relevant at this regulatory checkpoint. Through cAMP-PKA/CREB signaling, VIP may suppress pro-inflammatory transcriptional programs mediated by NF-κB, AP-1, IRF, and selected JAK/STAT pathways, thereby reducing the expression of TNF-α, IL-1β, IL-6, IL-12, iNOS/NO, and other inflammatory mediators (El-Salhy et al., 2017; Foey et al., 2003). At the same time, VIP enhances anti-inflammatory and pro-resolving signals such as IL-10, allowing inflammatory responses to shift gradually toward reparative immunity (Foey et al., 2003; Chu et al., 2020). Thus, VIP does not merely suppress inflammation; rather, it recalibrates the balance between pro-inflammatory and anti-inflammatory programs, potentially creating a microenvironment that favors the transition of chronic wounds toward proliferation and repair (Ganea et al., 2015; Louati et al., 2013).

Macrophages are major cellular targets through which VIP may regulate the chronic wound microenvironment. DFUs, pressure ulcers, and VLUs all display varying degrees of impaired macrophage phenotypic switching, typically characterized by persistent pro-inflammatory macrophage activity and insufficient M2-like reparative responses (Rodrigues et al., 2019). Through VPAC1/VPAC2-cAMP-PKA signaling, VIP can reduce TLR/NF-κB-mediated inflammatory mediator release and enhance IL-10 expression through CREB-associated mechanisms, thereby favoring macrophage states associated with inflammatory resolution and tissue repair (Ganea et al., 2015). VIP also regulates dendritic cell (DC) differentiation and maturation, induces tolerogenic DCs, and subsequently promotes regulatory T cell (Treg) responses. By suppressing Th1-associated inflammatory responses and promoting regulatory immune networks, VIP contributes to immune tolerance and inflammatory homeostasis (Mathews et al., 2006; Murphy et al., 2008). Although much of this evidence originates from general inflammatory or immune-cell models rather than chronic wound models, these actions may help alleviate the persistent immune activation and tissue destruction characteristic of chronic wounds. These immunoregulatory effects may also indirectly reshape macrophage metabolic states by reducing inflammatory stress conditions that sustain glycolytic activation.

In addition to immunomodulation, VIP may contribute to re-epithelialization and angiogenesis. Keratinocytes function not only as the principal epithelial cells responsible for wound healing, but also as important signaling hubs that regulate angiogenesis and local inflammation (Zhang and Ferre-D'Amare, 2014; Gerdes et al., 2023). In cultured human HaCaT keratinocytes VIP increased VEGF expression in keratinocytes, potentially through MAPK pathway activation.Epithelial injury models further suggest that VIP may facilitate epithelial-cell migration, proliferation, and wound healing. Thus, VIP may support wound healing through two complementary mechanisms: promoting keratinocyte migration and proliferation to accelerate re-epithelialization, and increasing VEGF expression to support neovascularization and granulation tissue development. Given that DFUs, pressure ulcers, and VLUs all involve impaired angiogenesis and defective re-epithelialization, VIP-mediated epithelial and vascular repair may have therapeutic relevance (Gerdes et al., 2023).

The relationship between VIP and wound metabolic reprogramming should be interpreted with caution. Chronic diabetic wounds are typically exposed to hyperglycemia, hypoxia, infection, and necrotic tissue-derived stimuli, conditions that favor a pro-inflammatory macrophage metabolic profile characterized by enhanced glycolysis, mitochondrial dysfunction, increased ROS, and sustained NF-κB/HIF-1α activation (Kvich et al., 2020; Pollock et al., 2019). By suppressing NF-κB, increasing IL-10, promoting Treg responses, and improving angiogenesis, VIP may indirectly reduce the persistent influence of pro-inflammatory glycolytic programming within the wound microenvironment and support a shift toward macrophage states more dependent on oxidative phosphorylation, fatty acid oxidation, and tissue repair (Pradhan et al., 2009; Jha et al., 2015; Ganea et al., 2015). In this sense, VIP is more likely to participate in immunometabolic reprogramming indirectly by reshaping the inflammatory milieu and improving oxygen availability, rather than acting as a direct metabolic switch from glycolysis to oxidative phosphorylation (Pollock et al., 2019; Chu et al., 2020).

Overall, VIP in chronic wounds is characterized by multi-target activity, cell-context dependence, and microenvironmental modulation. It can restrain macrophage- and T cell-mediated persistent inflammation while promoting reparative transition through VEGF/MAPK, cAMP/PKA/CREB, and Treg-associated signaling. Unlike purely pro-angiogenic or anti-inflammatory factors, VIP may function as both an inflammatory brake and a repair-switching mediator within the wound neuroimmune network. Future VIP-based therapeutic development should move beyond simple exogenous supplementation and focus on local delivery, receptor-subtype selectivity, peptide stabilization, and integration with carrier platforms such as hydrogels, microneedles, or extracellular vesicles. Only when applied at the appropriate wound phase, local concentration, and delivery mode is the VIP-VPAC axis likely to become a translationally meaningful target for neuroimmune therapy in chronic wounds. Human VIP itself is generally considered a single 28-amino-acid mature peptide rather than a group of wound-relevant isoforms (Frisch and Revelle, 1970). PACAP-27 and PACAP-38 are alternative processing products of the ADCYAP1 precursor and represent related PACAP-family ligands rather than VIP isoforms (Stanojevic et al., 2009). Both PACAP variants can activate PAC1 and, to a lesser extent, VPAC receptors, but PACAP-38 and PACAP-27 differ in tissue distribution, stability, and receptor pharmacological properties. For example, PACAP-38 exhibits greater potency than PACAP-27 in inducing plasma extravasation in rat skin, suggesting that processing-dependent differences may influence biological responses (Michel et al., 2002). However, the relative contribution of PACAP-27 and PACAP-38 to chronic cutaneous wound healing remains insufficiently characterized.

3.5. Other candidate neuropeptides for wound healing

Beyond SP, CGRP, NPY, and VIP, candidate neuropeptides should be separated according to direct wound evidence and molecular-form biology. Neuropeptide S (NPS) has been investigated in keratinocyte, fibroblast, endothelial, and neural systems, and an MMP-responsive microneedle delivery system containing NPS has shown therapeutic potential in diabetic rodent wound models (Gao et al., 2026). In contrast, α-melanocyte-stimulating hormone (α-MSH) has been reported to modulate inflammatory responses and later scar formation during murine excisional wound healing (de Souza et al., 2015).

By contrast, NPFF and its precursor-related peptide NPAF activate NPFFR1/NPFFR2 and participate in pain–inflammation regulation, but their direct contribution to chronic cutaneous wound healing remains insufficiently characterized (Vishnivetskiy et al., 2000). PACAP-27/PACAP-38, somatostatin-14/somatostatin-28, galanin-family peptides, and oxytocin exhibit immunomodulatory, vascular, epithelial, or analgesic activities that may be relevant to tissue repair; however, wound-specific evidence remains heterogeneous or largely indirect.

These molecular forms are not interchangeable: PACAP-27 and PACAP-38, as well as somatostatin-14 and somatostatin-28, are generated through precursor processing and display differences in stability, receptor interaction, and tissue distribution (Stanojevic et al., 2009). Galanin and galanin-like peptide (GALP) are encoded by distinct genes rather than representing isoforms of the same peptide precursor (Massad et al., 2014). NPS and oxytocin are generally regarded as single principal mature human peptides rather than families of wound-relevant molecular variants (Atanasoski et al., 2004; Gimpl and Fahrenholz, 2001). Accordingly, Table 1 classifies each candidate as established preclinical wound evidence, indirect skin/wound evidence, or hypothesis-generating evidence instead of presenting all candidates as equivalent therapeutic options.

4. Neuropeptide-driven advanced therapeutic strategies for chronic wounds

The therapeutic application of neuropeptides in chronic wounds is limited by their short half-life, rapid degradation, poor local retention, and context-dependent biological effects. To overcome these limitations, emerging strategies have focused on localized delivery, sustained or stimuli-responsive release, and combined neuroimmune modulation. Representative neuropeptide-based therapeutic strategies are illustrated in Figure 3.

FIGURE 3.

Infographic illustrating advanced neuropeptide-driven strategies for chronic wound therapy. Section A depicts sustained-release and microenvironment-responsive delivery using hydrogels, microspheres, and microneedles. Section B shows externally triggered delivery with engineered scaffolds, highlighting ultrasound-triggered hydrogels and nanofibers for ROS scavenging and angiogenesis. Section C presents cell-based therapy and neuropeptide engineering, including SKP-derived neural repair and sensory restoration. Section D outlines biophysical and combinatorial therapies, such as electrical stimulation, photobiomodulation, neuropeptide combinations, and anti-infective dressings. Central schematic demonstrates wound healing microenvironment, including biofilm, immune cells, and therapeutic interventions.

Representative neuropeptide-driven advanced therapeutic strategies for chronic wounds. The central illustration depicts major features of the chronic wound neuroimmune microenvironment, including biofilm formation, excessive reactive oxygen species, persistent inflammatory-cell activity, and impaired epithelial and stromal repair. (A) Sustained-release and microenvironment-responsive delivery systems improve local neuropeptide retention and enable release in response to pathological cues. Representative platforms include conventional sustained-release hydrogels, ROS-responsive SP hydrogels, glucose-responsive CGRP microspheres, and MMP-responsive microneedles carrying NPS and TIMP. (B) Externally triggered delivery systems and engineered scaffolds provide additional spatial and temporal control. Ultrasound-triggered CGRP hydrogels combine controlled peptide release with ROS scavenging and a transition from pro-inflammatory toward reparative macrophage states, whereas VIP-loaded electrospun nanofibers support sustained peptide presentation and angiogenic responses. (C) SKP-based cell therapy aims to restore local neuropeptide signaling and support reinnervation, angiogenesis, and sensory–immune–vascular repair through differentiation into sensory neuron-like cells and associated paracrine effects. (D) Biophysical approaches include electrical stimulation, which may mobilize endogenous CGRP and SP from residual sensory nerve terminals, and photobiomodulation, which may indirectly support neuropeptide-associated repair by improving the local metabolic and inflammatory microenvironment. Proposed combinatorial strategies include sequential neuroimmune modulation and paracrine repair using neuropeptides and MSC-sEVs, as well as anti-infective–neuropeptide dressings designed to couple biofilm control with inflammation resolution and tissue repair. Dashed arrows indicate proposed or early-preclinical therapeutic relationships that require further experimental validation. Abbreviations: CGRP, calcitonin gene-related peptide; ES, electrical stimulation; LLLT, low-level laser therapy; MMP, matrix metalloproteinase; MSC-sEVs, mesenchymal stromal cell-derived small extracellular vesicles; NPS, neuropeptide S; PBMT, photobiomodulation therapy; ROS, reactive oxygen species; SKPs, skin-derived precursors; SP, substance P; TENS, transcutaneous electrical nerve stimulation; TIMP, tissue inhibitor of metalloproteinases; VIP, vasoactive intestinal peptide. https://BioRender.com/2pg71wn.

4.1. Intelligent neuropeptide delivery systems: from sustained release to functional modulation

4.1.1. Hydrogel-based sustained-release platforms

Neuropeptides exert multiple biological functions during skin repair, including promoting epithelial regeneration, modulating immune responses, enhancing angiogenesis, and supporting nerve regeneration. However, their clinical use is limited by poor stability, rapid enzymatic degradation, and short in vivo half-lives, making it difficult to maintain therapeutically effective concentrations after direct administration. Accordingly, delivery systems capable of preserving peptide bioactivity while enabling sustained and controllable release have become a major focus in this field (Kim et al., 2018).

Hydrogels (HGs) are among the most established and widely used platforms for neuropeptide delivery. Composed of three-dimensional hydrophilic polymer networks, HGs can absorb wound exudate, maintain a moist microenvironment, and provide a scaffold-like matrix for cell migration and extracellular matrix (ECM) deposition (Ali et al., 2022; Jia et al., 2023). For neuropeptides, their most immediate advantages are enhanced local retention, reduced burst release, and protection from degradation (Keykhaee et al., 2023). For instance, a hydroxyethyl cellulose-based substance P gel (HEC-SP gel) is formed with 1.5% hydroxyethyl cellulose (HEC) and supplemented with 0.1% sodium thiosulfate and 0.006% polysorbate 80 to limit oxidative inactivation of substance P (SP) (Mukherjee and Ghosh, 2023). Although this formulation lacks sophisticated stimulus-responsive architecture, it is practically useful because it improves SP stability and prolongs local peptide action. By enhancing proliferation and migration of human epidermal keratinocytes and dermal fibroblasts, it may support re-epithelialization and granulation tissue formation. Its strengths include a simple formulation, mild preparation conditions, topical applicability, and a relatively low translational barrier. However, its release behavior depends mainly on passive diffusion and local adhesion, with limited responsiveness to pathological cues such as ROS, hyperglycemia, or matrix metalloproteinases (MMPs) (Kim et al., 2018; Zamani et al., 2026; Lai, 2021).To date, these approaches have been examined mainly through formulation characterization, keratinocyte and fibroblast assays, and rodent excisional-wound studies; a neuropeptide-loaded hydrogel has not yet been evaluated in a controlled trial of human chronic wounds.

In more tissue-engineering-oriented designs, carboxymethyl chitosan/gelatin hydrogel has been developed to co-deliver SP and dimethyloxalylglycine (DMOG). Cell-based assays and a rodent full-thickness wound model demonstrated that the SP/DMOG-loaded hydrogel promoted reparative-cell activity and accelerated wound healing, while DMOG enhanced HIF-1α stabilization and hypoxia-responsive pro-angiogenic signaling (Wang et al., 2023). A nonswellable Laponite nanodisc hydrogel has also been evaluated using a human tissue-engineered skin model, where sustained SP release promoted keratinocyte migration and re-epithelialization (De Serres-Berard et al., 2020).These studies remain preclinical and mainly demonstrate the feasibility of biomaterial-assisted SP delivery rather than clinical therapeutic efficacy.

CGRP-related hydrogels place greater emphasis on the neuroimmune–vascular axis. A GelMA-based CGRP co-crosslinked hydrogel was developed for diabetic wound treatment and evaluated using macrophage and endothelial-cell assays as well as diabetic mouse models. The system promoted a transition toward reparative macrophage states, suppressed inflammatory responses, enhanced IL-10/VEGFA-associated angiogenic signaling, improved endothelial migration and tube formation, and accelerated diabetic wound healing (Li et al., 2025).

Beyond hydrogel scaffolds, sustained-release CGRP delivery platforms have also been explored. A glucose-responsive antibacterial hydrogel microsphere system (BA-HPCS@CGRP) enabled controlled CGRP release and promoted diabetic wound healing by regulating macrophage polarization, enhancing endothelial function, and improving neurovascular regeneration (Zhao et al., 2026). In addition, an intelligent bilayer hydrogel capable of inflammation-responsive CGRP release was shown to modulate macrophage phenotype transition and improve angiogenic responses, further supporting the potential of CGRP-based biomaterials for coordinating neuroimmune–vascular repair (Wang et al., 2026).

However, these findings remain limited to in vitro and small-animal studies rather than clinical evidence. Future translational investigations should address CGRP stability after fabrication and storage, potential loss of bioactivity during crosslinking, local sensory and vascular effects, receptor adaptation or desensitization, and long-term tissue compatibility before clinical translation.

4.1.2. Stimuli-responsive and engineered delivery platforms

Stimuli-responsive delivery systems can be broadly classified into endogenous microenvironment-responsive systems and externally triggered systems. Endogenous systems exploit pathological biochemical cues within chronic wounds, including excessive reactive oxygen species (ROS), hyperglycemia, and elevated matrix metalloproteinase (MMP) activity, to regulate peptide release according to local disease conditions. In contrast, externally triggered systems respond to operator-controlled physical stimuli, such as ultrasound, thereby enabling on-demand and spatially controlled release. This classification distinguishes autonomous, pathology-adaptive release from release initiated by an externally applied stimulus (Liu et al., 2023).

Among endogenous microenvironment-responsive strategies, ROS-responsive nanoparticle-hydrogel composites provide an additional layer of control beyond conventional sustained-release hydrogels by coupling peptide release to oxidative stress within chronic wounds.A representative example is ROS-responsive SP@ZIF-8-PEG-TK@CA, in which substance P is loaded into zeolitic imidazolate framework-8 (ZIF-8) nanoparticles, coated with a polyethylene glycol-thioketal (PEG-TK) ROS-sensitive shell, and incorporated into a Ca2+-cross-linked alginate/pectin hydrogel (CA). Under high-ROS conditions, cleavage of thioketal bonds increases SP release, thereby coupling peptide delivery to the oxidative stress status of the chronic wound microenvironment (Zhu et al., 2020). Its reported performance is based on material and cell experiments together with full-thickness excisional wounds in rodents Functionally, this system promotes fibroblast proliferation, moderately enhances early inflammatory activation, and subsequently favors reparative macrophage states, supporting the transition from debridement-associated inflammation toward reparative inflammation. However, the translational use of metal-organic framework materials such as ZIF-8 still requires careful evaluation of long-term degradation behavior, metal ion release, and immunocompatibility.

The second endogenous strategy is glucose-responsive delivery, exemplified by hydrogel microspheres (HMs) that miniaturize and disperse the drug reservoir and are therefore well suited to irregular wound beds. Glucose-responsive BA-HPCS@CGRP HMs are composed of phenylboronic acid-grafted hydroxypropyl chitosan (BA-HPCS), GelMA, and CGRP, and are fabricated using microfluidic techniques (Turner et al., 2021). BA-HPCS provides glucose responsiveness and antibacterial activity, whereas GelMA protects CGRP and enables sustained release.The biological effects were assessed in endothelial and macrophage assays and in diabetic rodent wounds. By using hyperglycemia as a release trigger, this system aligns closely with the pathological characteristics of diabetic wounds. Mechanistically, CGRP can directly improve migration and tube formation in high-glucose-injured endothelial cells, promote macrophage polarization toward an M2 phenotype, and induce angiopoietin-like protein 4 (Angptl4) secretion, thereby further restoring endothelial function and promoting neurovascular regeneration (Zhao et al., 2026). The strengths of this platform include homogeneous distribution, pathological cue responsiveness, and combined antibacterial and immunomodulatory effects (Zhao et al., 2026). However, microfluidic scale-up, batch-to-batch reproducibility, and the reliability of local glucose concentration as a stable indicator of wound pathology remain to be validated.

The third endogenous strategy is MMP-responsive delivery, exemplified by microneedle (MN) systems that combine disease-specific release with improved penetration into deeper wound tissues. Functional neuropeptide S/tissue inhibitor of metalloproteinases liposome microneedles (FN-MN) use silk fibroin/gelatin hydrogel microneedles (SF/Gel MNs) as the structural framework, with transglutaminase 2 (TGM2) crosslinking to improve mechanical stability. Neuropeptide S (NPS) and tissue inhibitor of metalloproteinases (TIMP) are encapsulated within PLGLAG peptide-modified liposomes, in which the PLGLAG sequence can be cleaved by MMPs overexpressed in diabetic wounds to enable enzyme-responsive release.The study combined keratinocyte, fibroblast, endothelial, and neural cell assays with a diabetic rodent wound model. Once released, NPS promotes keratinocyte and fibroblast migration and proliferation while enhancing angiogenesis and nerve regeneration; TIMP suppresses excessive MMP activity and reduces persistent ECM degradation (Gao et al., 2025). The key advantage of this system is that it uses excessive matrix metalloproteinase (MMP) activity as a disease-specific release cue while improving local drug penetration through MN arrays. However, current evidence is still largely derived from animal models. Human chronic wounds are more complex with respect to skin thickness, stratum corneum integrity, infection burden, and biofilm formation. Therefore, the mechanical stability, comfort of administration, dressing-change interval, and long-term safety of MN systems require further validation.No corresponding study in human chronic wounds has been reported.

By contrast, ultrasound-responsive delivery represents an externally triggered strategy in which release is initiated or modulated by an applied physical stimulus. In this system, manganese porphyrin (MnP) and CGRP are first conjugated to form an amphiphilic prodrug, MnP-CGRP (MC). MC is then self-assembled with folic acid-modified DSPE-PEG-FA into targeted nanoparticles (MCF), which are subsequently incorporated into a Ca2+-cross-linked alginate hydrogel (CA). Upon ultrasound stimulation, the nanotherapeutic is released on demand.Evaluation to date has combined macrophage and material assays with experiments in diabetic mouse wounds. The design integrates several complementary functions: folic acid facilitates targeting of pro-inflammatory macrophages, MnP scavenges ROS, and CGRP favors reparative macrophage polarization. Reduced ROS levels may also help restore expression of receptor activity-modifying protein 1 (RAMP1), thereby enhancing macrophage responsiveness to CGRP (Li et al., 2026). The major advantage of this system is that the release profile can be externally controlled by ultrasound, making it potentially suitable for long-term, stage-adapted therapy in chronic wounds. However, reliance on external equipment, variability in ultrasound parameters, wound depth, and exudate conditions may complicate clinical implementation.

Electrospinning represents a scaffold-fabrication strategy rather than an independent peptide-release mechanism and can complement hydrogel-, nanoparticle-, microsphere-, microneedle-, and cell-mimetic platforms for constructing bioactive regenerative interfaces. Electrospun nanofibers possess structural features resembling native extracellular matrix (ECM), including nanoscale fibrillar architecture and anisotropic organization, while their high surface-to-volume ratio and tunable physicochemical properties enable versatile incorporation of bioactive molecules. Neuropeptides can be introduced into electrospun scaffolds through multiple approaches, including blend electrospinning, coaxial or emulsion encapsulation, post-spinning surface immobilization, and microsphere–fiber hybrid systems (Salles et al., 2019; Hao et al., 2026).

Although neuropeptide-functionalized electrospun scaffolds remain less extensively explored than hydrogel-based systems, available studies demonstrate their potential for regenerative applications. SP-conjugated chitosan nanofibers were developed as a bioactive scaffold capable of sustained SP presentation, which enhanced human mesenchymal stromal cell attachment, migration, and recruitment-associated responses in vitro (Kim et al., 2016). In another study, VIP-loaded microspheres incorporated into dopamine-modified poly (ε-caprolactone) (PCL) nanofibrous membranes enabled sustained VIP release and promoted endothelial angiogenic responses and wound healing in a rodent full-thickness wound model (Wang et al., 2016). These findings suggest that electrospun scaffolds can serve not only as structural matrices but also as spatially controlled platforms for neuropeptide presentation and regulation of regenerative cell behaviors.

Recent advances in electrospinning have further expanded its application in tissue regeneration through multifunctional and hybrid fabrication strategies. Electrospun scaffolds capable of regulating bioelectrical microenvironments, integrating conductive components, or combining multiple functional elements have been developed to improve cell–material interactions and tissue repair outcomes (Hao et al., 2025; Hao et al., 2026). However, several challenges remain before neuropeptide-functionalized electrospun materials can be translated into clinical wound therapies. These include potential peptide instability during organic-solvent exposure or high-voltage processing, residual solvent contamination, burst release, sterilization-associated loss of bioactivity, mechanical handling limitations of fiber mats, manufacturing scalability, and batch-to-batch reproducibility (Hao et al., 2026; Salles et al., 2019). Future strategies, such as coaxial aqueous-core electrospinning, post-fabrication peptide conjugation, standardized peptide potency assays, and evaluation in protease-rich human wound fluids, may improve the stability, controllability, and translational potential of these platforms.

Beyond these material-based platforms, macrophage-loaded or macrophage-biomimetic nanodelivery systems represent a promising future direction. Macrophages naturally exhibit inflammatory chemotaxis, barrier-crossing capacity, nanoparticle phagocytosis, and immune microenvironment modulation (Chan et al., 2022; Massad et al., 2014). Conventional nanocarriers often suffer from limited targeting efficiency, rapid clearance, and heterogeneous release, whereas macrophage membrane-coated nanoparticles, macrophage-derived small extracellular vesicles, or macrophage-derived nanovesicles may help address these limitations (Welsh et al., 2024; Xing et al., 2021; Jo et al., 2025). This strategy is particularly attractive for immunomodulatory neuropeptides such as CGRP, VIP, and NPY: the carrier can preferentially accumulate in inflamed wound tissue, while the neuropeptide cargo promotes a transition from pro-inflammatory toward reparative macrophage states, decreases TNF-α, IL-6, and IL-1β, and increases IL-10, TGF-β, and VEGF expression. (Li et al., 2025; Zhang and Ferre-D'Amare, 2014; Schroeder et al., 2017). In this context, the delivery system does more than transport a drug; it participates in immune reprogramming (Xing et al., 2021; Jo et al., 2025). At present, however, this approach remains largely platform-inspired. Its application to neuropeptide delivery will require solutions for low small extracellular vesicles (sEVs) yield, purification difficulty, source heterogeneity, unstable loading efficiency, and complex quality control (Bozoglan and Dundar, 2021).

4.2. Cell-based therapy and neuropeptide engineering

Persistent sensory nerve injury in chronic wounds causes not only impaired nociception but, more importantly, loss of neuropeptide signaling derived from sensory nerve terminals (Brain, 1997). Beyond direct supplementation of exogenous neuropeptides, cell-based approaches aimed at locally reconstructing the sensory nerve-immune-vascular regulatory axis are emerging as a more extensible therapeutic strategy. Skin-derived precursors (SKPs) are multipotent precursor cells isolated from adult skin with neural crest-associated properties and the capacity to differentiate into neural and mesenchymal lineages. Under appropriate in vitro induction conditions, human SKPs can differentiate into functional sensory neuron-like cells and respond to histamine, PAR2 agonists, TRPA1 agonists, and TRPV1 agonists, indicating partial sensory neuronal functionality (Toma et al., 2005; Bataille et al., 2020). In denervated skin wound models, SKP transplantation accelerates re-epithelialization, increases local cell proliferation and nerve fiber density, and elevates NGF, SP, and CGRP levels. These findings suggest that the pro-healing effects of SKPs may arise not only from general trophic support, but also from local nerve regeneration and restoration of the neuropeptide microenvironment (Shu et al., 2015). In diabetic wound models, SKPs have also been shown to promote wound healing and early angiogenesis; when combined with scaffolds such as collagen sponges, they further improve local cell survival and capillary regeneration (Ke et al., 2015; Sato et al., 2015). Thus, SKPs may be best viewed as a cell-based therapeutic strategy with vascular-supportive, reinnervating, and neuropeptide-paracrine potential, particularly for refractory wounds involving neuropathy, ischemia, and chronic inflammation.These conclusions derive from human SKP differentiation in vitro and transplantation into denervated or diabetic mouse wounds; clinical implantation has not been reported.

Induced pluripotent stem cells (iPSCs)-derived sensory neurons are best considered an in vitro platform for disease modeling and screening, and are not yet suitable as implantable wound-repair therapeutics (Konda et al., 2021; Delot and Vilain, 2021). Human pluripotent stem cells can be differentiated into nociceptor-like neurons expressing TRPV1, Nav1.7, Nav1.8, TAC1/SP, and CGRP and displaying stimulus-evoked electrophysiological responses (Messina et al., 2022; Chambers et al., 2012). However, implantation into a peripheral wound would not by itself recreate the normal architecture in which neuronal cell bodies reside in dorsal-root ganglia and project long axons to skin. Functional integration would require survival, oriented axonal growth, appropriate target innervation, vascular support, and safe synaptic/afferent connectivity (Delot and Vilain, 2021). Additional risks include residual undifferentiated cells and tumorigenicity, genomic instability, immune rejection, ectopic excitability, pain or dysesthesia, and poorly controlled peptide release (Galbusera et al., 2019). Accordingly, near-term translational uses should prioritize patient-specific in vitro models, drug screening, and engineered neural tissues with defined lineage purity; any implantation strategy requires rigorous lineage purification, biodistribution, electrophysiological, tumorigenicity, and long-term safety testing (Chambers et al., 2012).

Taken together, neuropeptide-based therapeutic strategies are shifting from simple peptide supplementation toward locally retained, stimuli-responsive, and microenvironment-adapted interventions. Hydrogels, nano-hydrogel composites, hydrogel microspheres, microneedles, cell- and vesicle-based approaches, biophysical stimulation, and combination dressings each address different pathological barriers in chronic wounds, including peptide instability, excessive inflammation, impaired angiogenesis, defective re-epithelialization, extracellular matrix degradation, and insufficient neural repair. Representative neuropeptide-based delivery systems and therapeutic platforms are summarized in Table 2.

TABLE 2.

Emerging neuropeptide-based therapeutic strategies for chronic wound healing: mechanisms, evidence, and translational limitations.

Strategy/platform Cargo and control cue Evidence level/model Principal finding Translational limitation Representative references
Conventional SP hydrogels SP or SP + DMOG; passive sustained release In vitro keratinocyte/fibroblast assays; rodent full-thickness wounds Improved retention, reparative-cell activity, epithelialization and angiogenesis Passive release; storage, oxidation, sterilization and potency specifications needed (Kim et al., 2018)
(Wang et al., 2023)
ROS-responsive SP nano-hydrogel
SP@ZIF-8-PEG-TK@CA
SP; ROS-cleavable thioketal Material/cell testing; rodent full-thickness excisional wounds ROS-coupled release and improved wound healing MOF degradation, metal-ion exposure, burst release and scale-up (Zhu et al., 2020)
CGRP co-crosslinked hydrogel CGRP; sustained local release Macrophage/endothelial assays; diabetic mice Reparative macrophage responses, angiogenesis and wound healing Isoform frequently unspecified; receptor desensitization and long-term local safety unresolved (Li et al., 2025)
Ultrasound-triggered CGRP hydrogel
MCF@CA
MnP-CGRP; ultrasound-triggered release In vitro macrophage/material assays; diabetic mice ROS scavenging plus neuroimmune modulation External device, acoustic dosimetry, depth/exudate effects and manufacturability (Li et al., 2026)
Glucose-responsive CGRP microspheres
BA-HPCS@CGRP
CGRP; hyperglycemia-responsive release Endothelial/macrophage assays; diabetic rodents Neurovascular regeneration and wound healing Microfluidic scale-up, batch reproducibility and clinically relevant glucose-response range (Zhao et al., 2026)
MMP-responsive NPS/TIMP microneedles NPS and TIMP; MMP-cleavable liposome module Multiple cell assays; diabetic rodent wounds Skin, vascular and nerve regeneration with inflammatory/ECM control Multicomponent causality, skin mechanics, irritation, dosing interval and human validation (Gao et al., 2025)
Electrospun neuropeptide scaffolds SP surface conjugation; VIP microspheres in PCL nanofibers; possible electroactive control SP: human MSC assays; VIP: endothelial assays and rodent wounds; broader electrospinning evidence ECM-mimetic architecture, tunable peptide presentation and sustained release Solvent/high-voltage bioactivity loss, residual solvent, burst release, sterilization and scale-up (Kim et al., 2016; Wang et al., 2016; Hao et al., 2025; Hao et al., 2026)
SKP-based neural repair Endogenous SP/CGRP restoration through cell therapy In vitro sensory-neuron differentiation; denervated/diabetic mouse wounds Reinnervation, trophic support and increased local neuropeptides Cell identity, survival, integration, manufacturing and long-term safety (Shu et al., 2015; Bataille et al., 2020)
iPSC-derived sensory neurons Neuropeptidergic nociceptor-like cells In vitro differentiation/disease modeling; no wound implantation efficacy Useful for patient-specific screening and mechanistic testing Tumorigenicity, lineage purity, ectopic excitability, pain and inability to recreate DRG–skin architecture (Chambers et al., 2012)
Electrical stimulation Mobilization of endogenous SP/CGRP/NPY/VIP-associated signaling Animal studies; acute human punch wounds; broader chronic-wound clinical literature Perfusion, inflammatory transition, reinnervation and repair signaling Waveform/dose heterogeneity; peptide-specific causal evidence in human chronic wounds is limited (Sebastian et al., 2011; Verdes et al., 2022)
Photobiomodulation Predominantly endogenous SP-associated signaling; mitochondrial CCO Animal skin peptide measurements; broader preclinical/clinical PBMT evidence Metabolic support and possible neuropeptide mobilization Direct CGRP/NPY/VIP causality and chronic-wound dose response remain unproven (Hochman et al., 2014; Avci et al., 2013)
MSC-sEV plus neuropeptide combination sEV cargo plus SP/CGRP; proposed sequential or co-delivery Conceptual/early preclinical; direct combination efficacy not established Potential neuroimmune recalibration followed by paracrine repair EV identity, cargo heterogeneity, dose, loading, biodistribution and combination-potency assays (Welsh et al., 2024; Zhang et al., 2018)
Anti-infective dressing plus neuropeptide module Antimicrobial component followed by SP/CGRP/VIP/NPY support Individual modules: in vitro/rodent; integrated strategy largely conceptual Infection control followed by inflammation resolution, angiogenesis and repair Must demonstrate added benefit beyond standard antimicrobial and wound care (Versey et al., 2021)

Abbreviations: BA-HPCS, boronic-acid-functionalized hydroxypropyl chitosan; CA, calcium-ion-cross-linked alginate/pectin hydrogel; CCO, cytochrome c oxidase; CGRP, calcitonin gene-related peptide; DMOG, dimethyloxalylglycine; DRG, dorsal root ganglion; ECM, extracellular matrix; ES, electrical stimulation; EV, extracellular vesicle; FA, folic acid; iPSC, induced pluripotent stem cell; MCF, manganese-porphyrin-CGRP/folic-acid-modified nanoparticle; MnP, manganese porphyrin; MMP, matrix metalloproteinase; MOF, metal-organic framework; MSC, mesenchymal stromal cell; NPS, neuropeptide S; PBMT, photobiomodulation therapy; PCL, poly (ε-caprolactone); PEG, polyethylene glycol; ROS, reactive oxygen species; sEV, small extracellular vesicle; SKP, skin-derived precursor; SP, substance P; TIMP, tissue inhibitor of metalloproteinases; TK, thioketal; VIP, vasoactive intestinal peptide; ZIF-8, zeolitic imidazolate framework-8.

4.3. Electrical stimulation and biophysical modulation

Electrical stimulation (ES) is one of the most extensively investigated biophysical adjuncts for chronic wound management, with reported benefits in local perfusion, tissue oxygenation, and reparative cell migration. In the context of neuropeptide regulation, its key relevance lies in the activation of residual sensory nerve terminals (Verdes et al., 2022; Milne et al., 2021). ES can depolarize nerve fibers and promote calcium influx through voltage-gated calcium channels (VGCCs), thereby inducing the release of neuropeptides such as CGRP and SP(Juckett et al., 2022). Animal studies indicate that neuropeptide responses vary according to stimulation frequency: low-frequency transcutaneous electrical nerve stimulation (TENS) appears to favor CGRP-associated vasodilatory responses, whereas higher-frequency stimulation more prominently involves SP(Khalil et al., 2001). Beyond CGRP and SP, ES may also modulate NPY- and vasoactive intestinal peptide (VIP)-related signaling. Human cutaneous wound studies have reported increased NPY and SP expression after ES, together with increased PGP9.5-positive and NPY-positive nerve fibers, suggesting that ES may promote wound reinnervation and enhance neuropeptide-mediated repair. Another human punch-wound study found that degenerate waveform ES upregulated VIP and interleukin-10 (IL-10) while reducing CD3-positive T cell infiltration, implying that ES may facilitate an inflammatory-to-reparative transition through VIP-associated anti-inflammatory effects (Sebastian et al., 2011). Nevertheless, NPY and VIP should be interpreted as distinct components of wound neuroimmune regulation. NPY is mainly associated with sympathetic nerve terminals and is involved in vascular tone, immune responses, and angiogenesis, whereas VIP displays clearer anti-inflammatory and immunomodulatory properties, largely through cAMP-related signaling. These findings suggest that ES may not only activate sensory neuropeptide pathways but also engage autonomic nerve-associated inflammatory and vascular regulation. However, current evidence is derived mainly from animal studies, acute human skin wound models, or exploratory investigations; direct validation in DFUs, pressure injuries, and VLUs remains limited (Ivanov et al., 2023).

Low-level laser therapy (LLLT), also referred to as photobiomodulation therapy (PBMT), primarily acts through red or near-infrared light targeting mitochondrial cytochrome c oxidase (CCO) (Greben et al., 2023; Avci et al., 2013). This interaction can influence ATP production, nitric oxide release, and reactive oxygen species (ROS) levels, thereby improving cellular metabolism, vascular responses, and inflammatory status. Compared with ES, evidence that LLLT directly induces neuropeptide release is more limited (Chung et al., 2012; Greben et al., 2023). Relatively direct animal skin studies suggest that 808 nm near-infrared LLLT can increase SP release, whereas CGRP levels may remain unchanged. Thus, LLLT may influence sensory nerve function and neuropeptide-associated repair responses indirectly by improving the local metabolic and inflammatory microenvironment. Current evidence provides some support for LLLT-induced SP release in animal models, but direct evidence for CGRP, NPY, and VIP release remains insufficient. (Hochman et al., 2014)., and peptide-specific efficacy has not been demonstrated in human chronic wounds.

Overall, ES more directly activates sensory nerve terminals and may therefore serve as a candidate approach for mobilizing endogenous CGRP/SP signaling. By contrast, LLLT appears to create a more permissive environment for neuropeptide-associated repair by improving cellular metabolism and local inflammatory status. Both modalities may complement neuropeptide-derived therapies for chronic wounds. However, high-quality studies that simultaneously assess intervention parameters, local neuropeptide dynamics, and healing outcomes in human chronic wounds are still needed.

4.4. Combinatorial therapeutic strategies

4.4.1. Potential synergy between neuropeptides and mesenchymal stromal cell-derived small extracellular vesicles

Mesenchymal stromal cell-derived small extracellular vesicles (MSC-sEVs) are nanoscale extracellular vesicles secreted by MSCs, typically 30–150 nm in diameter, and are enriched with diverse bioactive cargoes, including miRNAs, mRNAs, proteins, lipids, and metabolic regulatory molecules (Mulcahy et al., 2014; Ma et al., 2020; Welsh et al., 2024). Through membrane fusion or receptor-mediated endocytosis, these vesicles deliver signaling molecules to recipient cells, thereby reproducing stem cell-like paracrine effects without the need for direct cell transplantation. In recent years, MSC-sEVs have therefore been widely investigated in tissue repair including chronic wound models (Mulcahy et al., 2014; Ma et al., 2020; Zhang et al., 2018). The wound-repair evidence for MSC-sEVs is derived chiefly from cell and rodent studies, and direct neuropeptide-MSC-sEV combination efficacy has not yet been established.

Compared with direct MSC administration, MSC-sEVs offer several advantages. They are less immunogenic, are structurally stable, and are easier to store and transport, and lack proliferative capacity, thereby reducing concerns related to tumor formation. These properties have motivated their development as a cell-free alternative to direct MSC transplantation. Within the chronic wound microenvironment, MSC-sEVs act through multiple targets: they promote a transition toward reparative macrophage states, suppress excessive inflammation, enhance endothelial migration and angiogenesis, and stimulate fibroblast activation and collagen deposition. Through these effects, they may facilitate the transition of chronic wounds from inflammation toward proliferation and remodeling (Zhang et al., 2018).

At the mechanistic level, MSC-sEVs are enriched with miRNAs, including miR-21, miR-126, and miR-146a, that can regulate NF-κB, PI3K/Akt, Wnt/β-catenin, and other signaling pathways involved in inflammation control, angiogenesis, and cell migration. EV-associated proteins may also directly mediate intercellular communication. For instance, Wnt4 carried by human umbilical cord MSC-derived small extracellular vesicles can activate the Wnt/β-catenin signaling pathway and promote cutaneous injury repair. These properties support MSC-sEVs as a promising cell-free therapeutic platform (Hu et al., 2018; Tao et al., 2017).

However, chronic wounds are often characterized by neuroimmune dysregulation, which may compromise the consistency of sEV-mediated therapeutic effects. In a combinatorial framework, neuropeptides may function primarily as early microenvironmental modulators. SP can enhance macrophage chemotaxis and phagocytosis and help shift wounds from chronic inflammation toward repair. CGRP, through RAMP1-associated signaling, can act on neutrophils, monocytes, and macrophages to limit excessive inflammatory-cell recruitment, promote apoptotic-cell clearance, and support reparative macrophage polarization, thereby contributing to the initiation of tissue repair. Accordingly, combined neuropeptide and MSC-sEVs therapy can be conceptualized as a sequential intervention, progressing from neuroimmune microenvironmental recalibration to paracrine regenerative signaling (Lu et al., 2024). Neuropeptides first target dysregulated neuroimmune responses in chronic wounds and promote the transition from persistent inflammation to resolution; MSC-sEVs then deliver miRNAs, proteins, lipids, and other signaling molecules to further enhance angiogenesis, re-epithelialization, and ECM remodeling (Hu et al., 2018).

At present, evidence is still insufficient to determine whether neuropeptides can directly optimize the cargo composition or functional properties of MSC-sEVs, and the underlying mechanisms require further investigation. In this context, neuropeptide pretreatment of MSCs, hydrogel-mediated co-delivery of neuropeptides and MSC-sEVs, and staged-release systems may represent promising directions for future combinatorial therapy (Dubon and Park, 2015; Xu et al., 2021).

4.4.2. Neuropeptide-integrated anti-inflammatory dressings: combinatorial intervention for biofilm-associated chronic wounds

Biofilm formation is a major contributor to chronic wound nonhealing. Once bacteria form biofilms, they become embedded within an extracellular polymeric matrix, which confers substantial tolerance to antimicrobial therapy, host immune clearance, and external interventions. The pathological impact of biofilms extends beyond bacterial persistence; they can repeatedly activate neutrophils and macrophages, thereby maintaining the wound in a state of inefficient, chronic inflammation (Versey et al., 2021; Yuan et al., 2026; Lou et al., 2025). In this context, sustained release of ROS, proteases, and pro-inflammatory mediators can impair keratinocyte migration, granulation tissue formation, and collagen deposition. Therefore, antibacterial therapy alone or pro-reparative intervention alone is often insufficient to reverse inflammatory arrest and defective tissue regeneration (Chen et al., 2023; Huang et al., 2023).

For biofilm-associated chronic wounds, integrating anti-infective, anti-inflammatory, and neuroimmune-modulatory functions within a single material platform may provide a more targeted therapeutic strategy. The anti-infective component primarily reduces the local bacterial burden, attenuates biofilm-driven inflammatory stimulation, and enhances the local efficacy of antimicrobial agents (Jia et al., 2023; Xu et al., 2023). The neuropeptide component, in contrast, is intended to regulate inflammatory-cell behavior, promote inflammation resolution, improve vascular regeneration, and initiate tissue repair. Within such a composite system, different neuropeptides may play distinct roles (Leal et al., 2015). SP is mainly involved in inflammatory regulation and macrophage phenotypic switching, thereby improving chronic inflammation in diabetic wounds and promoting repair. CGRP, through CGRP receptor-associated signaling, can act on neutrophils, monocytes, and macrophages to limit excessive inflammatory-cell recruitment, enhance apoptotic-cell clearance, and promote reparative macrophage polarization, thereby supporting inflammation resolution and repair initiation (Lu et al., 2024). VIP may provide an additional anti-inflammatory and pro-angiogenic component. Although the individual antimicrobial and neuropeptide components are supported by in vitro or rodent studies, the fully integrated strategy remains conceptual or at an early preclinical stage.

Previous studies have shown that VIP and the related peptide PACAP can increase macrophage IL-10 production and suppress endotoxin-induced TNF-α release, supporting their potential roles in inflammatory regulation (Yu et al., 2010). In skin repair-associated cells, VIP can induce VEGF production by HaCaT keratinocytes, suggesting possible involvement in angiogenesis and epithelial repair. Delivery-system studies further support the feasibility of incorporating VIP into wound dressings. When VIP-loaded microspheres are integrated into dopamine-modified polycaprolactone nanofibrous membranes, they can establish a local microenvironment with spatiotemporally controlled release, thereby promoting wound healing and angiogenesis (Yu et al., 2010; Wang et al., 2016; Ekstrand et al., 2003). By contrast, direct evidence for NPY in biofilm-associated wounds remains limited; its potential value lies mainly in vascular regeneration and reparative immune modulation. The NPY-Y2R axis is closely linked to angiogenesis and cutaneous wound healing, as Y2 receptor deficiency can block NPY-induced angiogenesis and delay wound healing (Ekstrand et al., 2003). In addition, NPY can promote reparative macrophage polarization in human macrophages and enhance p62/SQSTM1-dependent autophagy and NRF2 activation, suggesting possible roles in inflammation control, oxidative stress attenuation, and the establishment of a reparative immune microenvironment (Profumo et al., 2022).

Existing neuropeptide-based material studies provide additional support for this combinatorial strategy. ROS-responsive SP@ZIF-8 nanoparticles incorporated into Ca2+-cross-linked alginate/pectin hydrogels can release SP in response to oxidative stress and promote wound healing (Zhu et al., 2020). In diabetic wound models, the combined use of SP and curcumin also shows potential for improving the inflammatory microenvironment and enhancing wound healing (Kant et al., 2017). For CGRP, sustained-release hydrogels can improve diabetic wound healing by promoting reparative macrophage polarization and angiogenesis. Moreover, studies of Cu-CGRP/PLLA composite dressings suggest that CGRP can be integrated with antibacterial or immunomodulatory material components to support immune regulation and tissue reconstruction in infected wounds (Li et al., 2025).

Overall, in biofilm-associated chronic wounds, SP, CGRP, VIP, and NPY are better positioned as neuroimmune-regulatory modules built upon anti-infective therapy, rather than as direct anti-biofilm agents. Their principal value lies in modulating inflammatory-cell behavior after persistent infectious stimulation has been reduced, thereby promoting inflammation resolution, vascular regeneration, and restoration of tissue-repair signaling. Such integration may provide more comprehensive microenvironmental support for chronic wound healing and offer a framework for temporally regulated repair platforms.

Overall, neuropeptide-based therapeutic strategies aim to improve peptide stability, prolong local retention, enable microenvironment-responsive release, and restore neuroimmune regulation within chronic wounds. Representative delivery systems and therapeutic platforms are summarized in Table 2.

5. Translational limitations and future directions

Although neuropeptide-mediated neuroimmune regulation offers a new therapeutic entry point for chronic wounds, its clinical translation remains constrained by several challenges. Chronic wounds are not a homogeneous disease entity. DFUs, pressure ulcers, and VLUs may all exhibit prolonged inflammation, insufficient vascularization, and repair arrest, but their etiological backgrounds and local microenvironments differ substantially (Pastar et al., 2023). DFUs are more strongly associated with peripheral neuropathy, hyperglycemic stress, and microvascular dysfunction; pressure ulcers are driven mainly by sustained compression, ischemia, hypoxia, and reperfusion injury; and VLUs are commonly linked to venous hypertension, leukocyte trapping, excessive protease activity, and chronic inflammation (Wang J. et al., 2025; Xia et al., 2025; Raffetto et al., 2020). Therefore, neuropeptide therapy should not be viewed as a broadly applicable pro-healing intervention but should be evaluated in relation to wound type, disease stage, and local neuroimmune status. At the molecular level, short half-lives, proteolysis in wound fluid, oxidation, and adsorption to containers or scaffold components may reduce exposure (Wen et al., 2022; Yang et al., 2022). Excessive or poorly timed signaling can also provoke pain, edema, vasodilation, vasoconstriction, hypotension, or inflammatory amplification, depending on the peptide and receptor context (Atci et al., 2017; Russell et al., 2014; Nie and Taylor, 2025).

Diabetic neuropathy may be one of the key determinants of neuropeptide therapeutic responsiveness. In DFUs, degeneration of sensory nerve fibers directly reduces local release of SP, CGRP, and other neuropeptides, thereby impairing neurogenic immune regulation, vascular responses, and repair initiation (Nowak et al., 2021). In patients with partially preserved neural function, electrical stimulation, photobiomodulation, or responsive delivery systems may enhance endogenous neuropeptide signaling. In contrast, in patients with advanced neuropathy, reliance on residual nerve terminals may be insufficient to generate stable therapeutic effects; exogenous neuropeptide supplementation, cell-based therapy, or engineered delivery systems may be required to reconstruct the local repair network (Avci et al., 2013; Verdes et al., 2022). Future studies should avoid treating patients with chronic wounds as a single undifferentiated population and should instead stratify them according to neuropathy severity, perfusion status, infection or biofilm burden, wound duration and depth, and molecular profiles of inflammatory, vascular, and neuropeptide-related signaling. Human DFU single-cell datasets provide a valuable foundation for identifying such biomarkers and patient-specific therapeutic targets, rather than assuming that all ulcers share identical cellular mechanisms (Theocharidis et al., 2022).

Receptor desensitization is another critical issue in long-term neuropeptide-based therapy. NK1R is targeted by SP, the CGRP receptor complex, VPAC1/VPAC2 targeted by VIP, and NPY-related Y receptors are largely G protein-coupled receptors. Sustained or excessive ligand stimulation can induce receptor phosphorylation, β-arrestin recruitment, receptor internalization, and downstream signal attenuation, thereby diminishing therapeutic efficacy (Ekstrand et al., 2003; Leal et al., 2015; Lu et al., 2024). The SP-NK1R axis illustrates this challenge: moderate activation supports inflammatory initiation, immune-cell recruitment, and reparative transition, whereas prolonged stimulation may cause NK1R desensitization and increase the risk of pain sensitization, vascular leakage, and inflammatory amplification (Suvas, 2017). Thus, neuropeptide therapy should not aim simply to intensify signaling, but to control timing, local concentration, and duration of exposure. Pulsatile release, phase-specific administration, receptor subtype-selective agonists, biased agonists, and protease-resistant neuropeptide analogs may help improve therapeutic stability while reducing adverse effects. (Wang et al., 2022; Jayakody et al., 2025). Cyclization, terminal capping, non-natural amino-acid substitution, lipidation, PEGylation, or albumin-binding motifs may improve stability, but every engineered analogue must be requalified for receptor potency, bias, human wound-fluid stability, pain, vascular effects, and immunogenicity (Wijesinghe et al., 2022; Tasdemiroglu et al., 2022; Xiao et al., 2025).

The neuroimmune microenvironment of chronic wounds is also marked by substantial cellular and spatial heterogeneity. Wound tissues contain neutrophils, macrophage subsets, T cells, keratinocytes, fibroblasts, endothelial cells, Schwann cells, and residual or regenerating nerve fibers. These populations form distinct functional microdomains across the wound bed, including inflammation-enriched regions, angiogenic zones, epithelial migration fronts, and nerve regeneration-associated areas. Single-cell sequencing and spatial transcriptomics can help define neuropeptide receptor expression, spatial localization, and treatment-induced state transitions in specific cell populations (Theocharidis et al., 2022; Dong et al., 2024). Future studies should integrate these omics approaches with protein-level validation, neuropeptide quantification, nerve fiber density assessment, and functional assays of inflammation resolution, angiogenesis, and re-epithelialization to more precisely define the roles of individual neuropeptides across wound types and repair stages. A staged validation path can connect these molecular maps to function: receptor-defined cell assays, human wound-fluid stability tests, multicellular skin equivalents, perfused skin- or DFU-on-chip systems, ex vivo human wounds, and disease-matched animal models. This sequence is more informative than relying only on closure in healthy rodents (Ejiugwo et al., 2021; Maggiotto et al., 2025).

The intrinsic instability of neuropeptides further limits their direct therapeutic use. Most neuropeptides have short half-lives and are susceptible to proteolytic degradation, while chronic wounds are often characterized by elevated ROS, hyperglycemia, abnormal pH, biofilm formation, and excessive MMP activity, all of which make it difficult to maintain effective local concentrations (Huang et al., 2023; Muller et al., 2008). Delivery system development is therefore a fundamental requirement for neuropeptide translation. Hydrogels, nanoparticles, microspheres, microneedles, and extracellular vesicles have shown potential to improve peptide stability, local retention, and pathology-responsive release. Before clinical application, however, these systems must still address manufacturing scalability, batch-to-batch consistency, release reproducibility, immunocompatibility, storage stability, and long-term safety (Lin et al., 2025; Barnum et al., 2020).

Responsive hydrogels, microspheres, microneedles, and electrospun composites are promising only if increasing responsiveness does not undermine reproducibility (Almudhi and Gabr, 2022; Rozanova et al., 2016). Quality-by-design should specify peptide identity, purity, potency, release after sterilization and storage, residual reagents, scaffold degradation, and batch consistency (Liu et al., 2021). EV-containing products additionally require MISEV2023-compliant characterization and a potency assay linked to the intended mechanism.

Overall, the future of neuropeptide therapy should move beyond single-molecule supplementation toward more precise neuroimmune modulation. Selection of neuropeptide type, administration timing, and delivery strategy should be guided by wound type, inflammatory phenotype, neuropathy severity, vascular status, and receptor expression profiles. Only when interventions are grounded in a clear understanding of the wound neuroimmune state can neuropeptides evolve from pro-reparative modulators into key tools for precision neuroimmune therapy in chronic wounds.

6. Conclusion

Chronic wound healing failure fundamentally reflects a multilayered imbalance among neural regulation, immune responses, vascular remodeling, and extracellular matrix remodeling. Persistent inflammation, impaired innervation, dysregulated neuropeptide signaling, defective angiogenesis, and failed inflammation resolution converge to keep the wound trapped in an inefficient inflammatory state. Neuropeptides such as SP, CGRP, NPY, and VIP can regulate macrophage polarization, restrain excessive neutrophil-driven inflammation, promote apoptotic-cell clearance, improve angiogenesis, promote re-epithelialization, and support ECM remodeling, thereby helping chronic wounds re-engage an orderly repair program.

Therefore, neuropeptides should be regarded not merely as pro-healing molecules, but as inflammatory remodeling mediators in chronic wounds. Their central value lies in restoring impaired neuroimmune crosstalk and disrupting the vicious cycle linking nerve injury, dysregulated neuropeptide signaling, persistent immune activation, and failed tissue repair. Because neuropeptide signaling is dose-dependent, phase-specific, and microenvironment-sensitive, future therapeutic strategies should prioritize localized, controllable, and precision-oriented intervention.

With advances in intelligent delivery systems, engineered cells, extracellular vesicles, electrical stimulation, and composite dressings, neuropeptide-based interventions could become more controllable, but translational progress will depend on human-tissue target engagement, disease-matched models, reproducible manufacturing, and peptide-specific safety. Integrating single-cell sequencing, spatial transcriptomics, and multi-omics analysis may enable individualized neuroimmune therapeutic strategies based on wound type, neuropathy severity, inflammatory status, and receptor expression profiles. Such approaches could provide new therapeutic routes to overcome chronic inflammatory arrest and restore tissue regeneration programs.

Future neuropeptide research should further integrate neurobiology, immunology, biomaterials science, and precision medicine.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Natural Science Foundation of China (82560932, 82460974).

Footnotes

Edited by: Stefano Bacci, University of Florence, Italy

Reviewed by: Bruno Paiva Dos Santos, Université Paris Cité, France

Zhuowen Hao, Wuhan University, China

Author contributions

JW: Conceptualization, Writing – original draft, Investigation, Validation. MZ: Conceptualization, Investigation, Visualization, Writing – original draft. HW: Writing – review and editing, Data curation, Investigation, Visualization. XD: Writing – review and editing, Data curation, Investigation, Visualization. DT: Conceptualization, Methodology, Validation, Writing – original draft. SX: Visualization, Data curation, Writing – original draft. TS: Data curation, Visualization, Writing – original draft. JL: Data curation, Validation, Writing – original draft. ZW: Writing – review and editing, Conceptualization, Supervision, Visualization. JW: Funding acquisition, Project administration, Supervision, Writing – review and editing. LX: Funding acquisition, Project administration, Supervision, Writing – review and editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Al Mamun A., Shao C., Geng P., Wang S., Xiao J. (2025). Recent advances in the role of neuroregulation in skin wound healing. Burns Trauma 13, tkae072. 10.1093/burnst/tkae072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ali F., Khan I., Chen J., Akhtar K., Bakhsh E. M., Khan S. B. (2022). Emerging fabrication strategies of hydrogels and its applications. Gels 8, 205. 10.3390/gels8040205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Almudhi A., Gabr S. A. (2022). Green tea consumption and the management of adrenal stress hormones in adolescents who stutter. Biomed. Rep. 16, 32. 10.3892/br.2022.1515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anderson Z. T., Dawson A. D., Slominski A. T., Harris M. L. (2022). Current insights into the role of neuropeptide Y in skin physiology and pathology. Front. Endocrinol. (Lausanne) 13, 838434. 10.3389/fendo.2022.838434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Armstrong D. G., Tan T. W., Boulton A. J. M., Bus S. A. (2023). Diabetic foot ulcers: a review. JAMA 330, 62–75. 10.1001/jama.2023.10578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Atanasoski S., Notterpek L., Lee H. Y., Castagner F., Young P., Ehrengruber M. U., et al. (2004). The protooncogene Ski controls schwann cell proliferation and myelination. Neuron 43, 499–511. 10.1016/j.neuron.2004.08.001 [DOI] [PubMed] [Google Scholar]
  7. Atci I. B., Yilmaz H., Antar V., Ozdemir N. G., Baran O., Sadillioglu S., et al. (2017). What do we know about ALARA? Is our knowledge sufficient about radiation safety? J. Neurosurg. Sci. 61, 597–602. 10.23736/S0390-5616.16.03418-4 [DOI] [PubMed] [Google Scholar]
  8. Avci P., Gupta A., Sadasivam M., Vecchio D., Pam Z., Pam N., et al. (2013). Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin. Cutan. Med. Surg. 32, 41–52. [PMC free article] [PubMed] [Google Scholar]
  9. Bailey S. D., Xie C., Do R., Montpetit A., Diaz R., Mohan V., et al. (2010). Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the diabetes REduction assessment with ramipril and rosiglitazone medication (DREAM) study. Diabetes Care 33, 2250–2253. 10.2337/dc10-0452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bardelli C., Gunella G., Varsaldi F., Balbo P., Del Boca E., Bernardone I. S., et al. (2005). Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway. Br. J. Pharmacol. 145, 385–396. 10.1038/sj.bjp.0706198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Barnum L., Samandari M., Schmidt T. A., Tamayol A. (2020). Microneedle arrays for the treatment of chronic wounds. Expert Opin. Drug Deliv. 17, 1767–1780. 10.1080/17425247.2020.1819787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bataille A., Leschiera R., L'Herondelle K., Pennec J.-P., Le Goux N., Mignen O., et al. (2020). In vitro differentiation of human skin-derived cells into functional sensory neurons-like. Cells 9 (4), 1000. 10.3390/cells9041000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bauer J. W., Lang R., Jakab M., Kofler B. (2008). Galanin family of peptides in skin function. Cell Mol. Life Sci. 65, 1820–1825. 10.1007/s00018-008-8156-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Beraud M., Hashami S. A., Lozano M., Bah A., Keith P. (2022). Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome. Transfus. Apher. Sci. 61, 103433. 10.1016/j.transci.2022.103433 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Blufpand H. N., Westland R., van Wijk J. A., Roelandse-Koop E. A., Kaspers G. J. L., Bökenkamp A. (2013). Height-independent estimation of glomerular filtration rate in children: an alternative to the Schwartz equation. J. Pediatr. 163, 1722–1727. 10.1016/j.jpeds.2013.08.031 [DOI] [PubMed] [Google Scholar]
  16. Boeringer T., Gould L. J., Koria P. (2020). Protease-resistant growth factor formulations for the healing of chronic wounds. Adv. Wound Care (New Rochelle) 9, 612–622. 10.1089/wound.2019.1043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Booe J. M., Walker C. S., Barwell J., Kuteyi G., Simms J., Jamaluddin M. A., et al. (2015). Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol. Cell 58, 1040–1052. 10.1016/j.molcel.2015.04.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Botchkarev V. A., Yaar M., Peters E. M., Raychaudhuri S. P., Botchkareva N. V., Marconi A., et al. (2006). Neurotrophins in skin biology and pathology. J. Invest Dermatol 126, 1719–1727. 10.1038/sj.jid.5700270 [DOI] [PubMed] [Google Scholar]
  19. Bozoglan A., Dundar S. (2021). Comparison of osseointegration of Ti-Al(6)V(4) and Ti-Al(6)Nb(7) implants: an experimental study. J. Oral Biol. Craniofac Res. 11, 624–627. 10.1016/j.jobcr.2021.09.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Brain S. D. (1997). Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology 37, 133–152. 10.1016/s0162-3109(97)00055-6 [DOI] [PubMed] [Google Scholar]
  21. Cao J., Belousoff M. J., Danev R., Christopoulos A., Wootten D., Sexton P. M. (2024). Cryo-EM structure of the human Amylin 1 receptor in complex with CGRP and Gs protein. Biochemistry 63, 1089–1096. 10.1021/acs.biochem.4c00114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Chagnon-Lessard S., Nicolai J., Steller J., Moo E. K., Jean-Ruel H. (2026). High-performance Brillouin spectroscopy using VIPA-etalon cascades. J. Biomed. Opt. 31, 026001–026015. 10.1117/1.jbo.31.2.026001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chambers S. M., Qi Y., Mica Y., Lee G., Zhang X. J., Niu L., et al. (2012). Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715–720. 10.1038/nbt.2249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chan D. Y. C., Cheung E. Y. H., Hui K. H., Leung C. M. S., Ng S. C. P., Mak W. K., et al. (2022). ABC/2 formula for “bedside” postoperative pneumocephalus volume measurement. Chin. Neurosurg. J. 8, 18. 10.1186/s41016-022-00287-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Chen Y., Wang X., Tao S., Wang Q., Ma P. Q., Li Z. B., et al. (2023). Research advances in smart responsive-hydrogel dressings with potential clinical diabetic wound healing properties. Mil. Med. Res. 10, 37. 10.1186/s40779-023-00473-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Cheret J., Lebonvallet N., Carre J. L., Misery L., Le Gall-Ianotto C. (2013). Role of neuropeptides, neurotrophins, and neurohormones in skin wound healing. Wound Repair Regen. 21, 772–788. 10.1111/wrr.12101 [DOI] [PubMed] [Google Scholar]
  27. Choi J. E., Di Nardo A. (2018). Skin neurogenic inflammation. Semin. Immunopathol. 40, 249–259. 10.1007/s00281-018-0675-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Choi B., Shin M. K., Kim E. Y., Park J. E., Lee H., Kim S. W., et al. (2019). Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell Formation. Front. Immunol. 10, 1701. 10.3389/fimmu.2019.01701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Chu C., Artis D., Chiu I. M. (2020). Neuro-immune interactions in the tissues. Immunity 52, 464–474. 10.1016/j.immuni.2020.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Chung H., Dai T., Sharma S. K., Huang Y. Y., Carroll J. D., Hamblin M. R. (2012). The nuts and bolts of low-level laser (light) therapy. Ann. Biomed. Eng. 40, 516–533. 10.1007/s10439-011-0454-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Damon D. H. (2008). TH and NPY in sympathetic neurovascular cultures: role of LIF and NT-3. Am. J. Physiol. Cell Physiol. 294, C306–C312. 10.1152/ajpcell.00214.2007 [DOI] [PubMed] [Google Scholar]
  32. Dasari N., Jiang A., Skochdopole A., Chung J., Reece E. M., Vorstenbosch J., et al. (2021). Updates in diabetic wound healing, inflammation, and scarring. Semin. Plast. Surg. 35, 153–158. 10.1055/s-0041-1731460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. de Lusignan S., Hinton W., Seidu S., Mathew M., Feher M. D., Munro N., et al. (2021). Dashboards to reduce inappropriate prescribing of metformin and aspirin: a quality assurance programme in a primary care sentinel network. Prim. Care Diabetes 15, 1075–1079. 10.1016/j.pcd.2021.06.003 [DOI] [PubMed] [Google Scholar]
  34. De Serres-Berard T., Becher T. B., Braga C. B., Ornelas C., Berthod F. (2020). Neuropeptide substance P released from a nonswellable laponite-based Hydrogel enhances wound healing in a tissue-engineered skin in vitro . Acs Appl. Polym. Mater. 2, 5790–5797. 10.1021/acsapm.0c01034 [DOI] [Google Scholar]
  35. de Souza K. S., Cantaruti T. A., Azevedo G. M., Jr., Galdino D. A. d. A., Rodrigues C. M., Costa R. A., et al. (2015). Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone. Exp. Dermatol 24, 198–203. 10.1111/exd.12609 [DOI] [PubMed] [Google Scholar]
  36. Delot E. C., Vilain E. (2021). Towards improved genetic diagnosis of human differences of sex development. Nat. Rev. Genet. 22, 588–602. 10.1038/s41576-021-00365-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Dickson L., Finlayson K. (2009). VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 121, 294–316. 10.1016/j.pharmthera.2008.11.006 [DOI] [PubMed] [Google Scholar]
  38. Dong Y., Wang M., Wang Q., Cao X., Chen P., Gong Z. (2024). Single-cell RNA-seq in diabetic foot ulcer wound healing. Wound Repair Regen. 32, 880–889. 10.1111/wrr.13218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Dubon M. J., Park K. S. (2015). Substance P enhances the proliferation and migration potential of murine bone marrow-derived mesenchymal stem cell-like cell lines. Exp. Ther. Med. 9, 1185–1191. 10.3892/etm.2015.2291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ejiugwo M., Rochev Y., Gethin G., O'Connor G. (2021). Toward developing immunocompetent diabetic foot Ulcer-on-a-Chip models for drug testing. Tissue Eng. Part C Methods 27, 77–88. 10.1089/ten.tec.2020.0331 [DOI] [PubMed] [Google Scholar]
  41. Ekstrand A. J., Cao R., Bjorndahl M., Nystrom S., Jonsson-Rylander A. C., Hassani H., et al. (2003). Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl. Acad. Sci. U. S. A. 100, 6033–6038. 10.1073/pnas.1135965100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. El-Salhy M., Solomon T., Hausken T., Gilja O. H., Hatlebakk J. G. (2017). Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. World J. Gastroenterol. 23, 5068–5085. 10.3748/wjg.v23.i28.5068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Espina C., Yared W., Ritchie D., Lipponen S., Anttila A., Tamminiemi K., et al. (2021). Sustainability and monitoring of the European code against cancer: recommendations. Cancer Epidemiol. 72, 101933. 10.1016/j.canep.2021.101933 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Falanga V., Isseroff R. R., Soulika A. M., Romanelli M., Margolis D., Kapp S., et al. (2022). Chronic wounds. Nat. Rev. Dis. Prim. 8, 50. 10.1038/s41572-022-00377-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Fang C., Bourdette D., Banker G. (2012). Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol. Neurodegener. 7, 29. 10.1186/1750-1326-7-29 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Fahrenkrug J. (1979). Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. Digestion 19, 149–169. 10.1159/000198339 [DOI] [PubMed] [Google Scholar]
  47. Fattori V., Zaninelli T. H., Rasquel-Oliveira F. S., Heintz O. K., Jain A., Sun L., et al. (2024). Nociceptor-to-macrophage communication through CGRP/RAMP1 signaling drives endometriosis-associated pain and lesion growth in mice. Sci. Transl. Med. 16, eadk8230. 10.1126/scitranslmed.adk8230 [DOI] [PubMed] [Google Scholar]
  48. Foey A. D., Field S., Ahmed S., Jain A., Feldmann M., Brennan F. M., et al. (2003). Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res. Ther. 5, R317–R328. 10.1186/ar999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Frisch R. E., Revelle R. (1970). Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 169, 397–399. 10.1126/science.169.3943.397 [DOI] [PubMed] [Google Scholar]
  50. Friston K. J. (1998). The disconnection hypothesis. Schizophr. Res. 30, 115–125. 10.1016/s0920-9964(97)00140-0 [DOI] [PubMed] [Google Scholar]
  51. Galbusera L., Finn M. T. M., Tschacher W., Kyselo M. (2019). Interpersonal synchrony feels good but impedes self-regulation of affect. Sci. Rep. 9, 14691. 10.1038/s41598-019-50960-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ganea D., Hooper K. M., Kong W. (2015). The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol. (Oxf) 213, 442–452. 10.1111/apha.12427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Gao S., Wang T., Han Z., Hu Y., Zhu P., Xue Y., et al. (2024). Interpretation of 10 years of Alzheimer's disease genetic findings in the perspective of statistical heterogeneity. Brief. Bioinform 25, bbae140. 10.1093/bib/bbae140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Gao Y., Cheng M., Wu Y., Zhang L., Xu B., Lu X. (2025). A smart functional microneedle, tethered with neuropeptide S and tissue inhibitor of metalloproteinases, promotes skin, vascular, and nerve regeneration for chronic diabetic skin wound healing. Small Struct. 6, 2500278. 10.1002/sstr.202500278 [DOI] [Google Scholar]
  55. Gao F., Hu Z., Xu H., Yu Y., Gao S., Sun J., et al. (2025). Hydrogel-extracellular vesicle engineering delivery system: a promising therapeutic strategy for wound healing. J. Nanobiotechnology 24, 375. 10.1186/s12951-026-04236-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Garcia-Recio S., Gascon P. (2015). Biological and pharmacological aspects of the NK1-Receptor. Biomed. Res. Int. 2015, 495704. 10.1155/2015/495704 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Gerdes M. E., Miko S., Kunz J. M., Hannapel E. J., Hlavsa M. C., Hughes M. J., et al. (2023). Estimating waterborne infectious disease burden by exposure route, United States, 2014. Emerg. Infect. Dis. 29, 1357–1366. 10.3201/eid2907.230231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Gimpl G., Fahrenholz F. (2001). The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 81, 629–683. 10.1152/physrev.2001.81.2.629 [DOI] [PubMed] [Google Scholar]
  59. Graiani G., Emanueli C., Desortes E., Van Linthout S., Pinna A., Figueroa C. D., et al. (2004). Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of type 1 diabetic mice. Diabetologia 47, 1047–1054. 10.1007/s00125-004-1414-7 [DOI] [PubMed] [Google Scholar]
  60. Grant D. S., Zukowska Z. (2000). Revascularization of ischemic tissues with SIKVAV and neuropeptide Y (NPY). Adv. Exp. Med. Biol. 476, 139–154. 10.1007/978-1-4615-4221-6_12 [DOI] [PubMed] [Google Scholar]
  61. Greben A. I., Eremin P. S., Kostromina E. Y., Markov P., Greben T., Gilmutdinova I., et al. (2023). Low level laser therapy: molecular mechanisms of anti-inflammatory and regenerative effects. Vopr. Kurortol. Fizioter. Lech. Fiz. Kult. 100, 61–68. 10.17116/kurort202310002161 [DOI] [PubMed] [Google Scholar]
  62. Hao Z. W., Zhang Z. Y., Wang Z. P., Wang Y., Chen J. Y., Chen T. H., et al. (2024). Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential. Mil. Med. Res. 11, 75. 10.1186/s40779-024-00576-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Hao Z., Wang Z., Wang Y., Dong M., Zhang Z., Chen J., et al. (2025). Electrospinning for mimicking bioelectric microenvironment in tissue regeneration. Research. 8, 0959. 10.34133/research.0959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Hao Z., Dong M., Wang Y., Wang Z., Zhang Z., Chen J., et al. (2026). Advancing electrospun nanofiber scaffolds for next-generation tissue engineering: from trend analysis to multifunctionalization and hybrid fabrication. Mater Horiz. 13, 1096–1137. 10.1039/d5mh01483b [DOI] [PubMed] [Google Scholar]
  65. Hauser R. A., Molho E., Shale H., Pedder S., Dorflinger E. E. (1998). A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone de novo Study Group. Mov. Disord. 13, 643–647. 10.1002/mds.870130406 [DOI] [PubMed] [Google Scholar]
  66. Heuer A., Stiel C., Elrod J., Königs I., Vincent D., Schlegel P., et al. (2021). Therapeutic targeting of neutrophil extracellular traps improves primary and secondary intention wound healing in mice. Front. Immunol. 12, 614347. 10.3389/fimmu.2021.614347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hochman B., Pinfildi C. E., Nishioka M. A., Furtado F., Bonatti S., Monteiro P. K. P., et al. (2014). Low-level laser therapy and light-emitting diode effects in the secretion of neuropeptides SP and CGRP in rat skin. Lasers Med. Sci. 29, 1203–1208. 10.1007/s10103-013-1494-z [DOI] [PubMed] [Google Scholar]
  68. Hong H. S., Lee J., Lee E., Kwon Y. S., Lee E., Ahn W., et al. (2009). A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat. Med. 15, 425–435. 10.1038/nm.1909 [DOI] [PubMed] [Google Scholar]
  69. Hu Y., Rao S. S., Wang Z. X., Cao J., Tan Y. J., Luo J., et al. (2018). Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function. Theranostics 8, 169–184. 10.7150/thno.21234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Huang F., Lu X., Yang Y., Yang Y., Li Y., Kuai L., et al. (2023). Microenvironment-based diabetic foot ulcer nanomedicine. Adv. Sci. (Weinh) 10, e2203308. 10.1002/advs.202203308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Ivanov E., Akhmetshina M., Erdiakov A., Gavrilova S. (2023). Sympathetic system in wound healing: multistage control in normal and diabetic skin. Int. J. Mol. Sci. 24, 2045. 10.3390/ijms24032045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Jayakody T., Budagoda D. K., Mendis K., Dilshan W. D., Bethmage D., Dissasekara R., et al. (2025). Biased agonism in peptide-GPCRs: a structural perspective. Pharmacol. Ther. 269, 108806. 10.1016/j.pharmthera.2025.108806 [DOI] [PubMed] [Google Scholar]
  73. Jha A. K., Huang S. C., Sergushichev A., Lampropoulou V., Ivanova Y., Loginicheva E., et al. (2015). Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430. 10.1016/j.immuni.2015.02.005 [DOI] [PubMed] [Google Scholar]
  74. Jia X., Dou Z., Zhang Y., Li F., Xing B., Hu Z., et al. (2023). Smart responsive and controlled-release hydrogels for chronic wound treatment. Pharmaceutics 15, 2735. 10.3390/pharmaceutics15122735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Jo H. Y., Kim M. K., Kim K. T., Choi C., Rhee W. J. (2025). Extracellular vesicles for macrophage reprogramming: an emerging paradigm in immunomodulatory therapeutics. J. Biol. Eng. 20, 13. 10.1186/s13036-025-00594-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Johnson M. B., Young A. D., Marriott I. (2016). The therapeutic potential of targeting substance P/NK-1R interactions in inflammatory CNS disorders. Front. Cell Neurosci. 10, 296. 10.3389/fncel.2016.00296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Juckett L., Saffari T. M., Ormseth B., Senger J. L., Moore A. M. (2022). The effect of electrical stimulation on nerve regeneration following peripheral nerve injury. Biomolecules 12, 1856. 10.3390/biom12121856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Kant V., Kumar D., Prasad R., Gopal A., Pathak N. N., Kumar P., et al. (2017). Combined effect of substance P and curcumin on cutaneous wound healing in diabetic rats. J. Surg. Res. 212, 130–145. 10.1016/j.jss.2017.01.011 [DOI] [PubMed] [Google Scholar]
  79. Ke T., Yang M., Mao D., Zhu M., Che Y., Kong D., et al. (2015). Co-Transplantation of skin-derived precursors and collagen sponge facilitates diabetic wound healing by promoting local vascular regeneration. Cell Physiol. Biochem. 37, 1725–1737. 10.1159/000438537 [DOI] [PubMed] [Google Scholar]
  80. Keykhaee M., Rahimifard M., Najafi A., Baeeri M., Abdollahi M., Mottaghitalab F., et al. (2023). Alginate/gum arabic-based biomimetic hydrogel enriched with immobilized nerve growth factor and carnosine improves diabetic wound regeneration. Carbohydr. Polym. 321, 121179. 10.1016/j.carbpol.2023.121179 [DOI] [PubMed] [Google Scholar]
  81. Khalil Z., Merhi M., Livett B. G. (2001). Differential involvement of conotoxin-sensitive mechanisms in neurogenic vasodilatation responses: effects of age. J. Gerontol. A Biol. Sci. Med. Sci. 56, B356–B363. 10.1093/gerona/56.8.b356 [DOI] [PubMed] [Google Scholar]
  82. Khanna S., Biswas S., Shang Y., Collard E., Azad A., Kauh C., et al. (2010). Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 5, e9539. 10.1371/journal.pone.0009539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Kim M. S., Park S. J., Cho W., Gu B. K., Kim C. H. (2016). Neuropeptide Substance-P-Conjugated chitosan nanofibers as an active modulator of stem cell recruiting. Int. J. Mol. Sci. 17 (1), 68. 10.3390/ijms17010068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Kim D. J., Jang J. H., Jang S. S., Lee J. (2018). A novel substance P-Based hydrogel for increased wound healing efficiency. Molecules 23 (9), 2215. 10.3390/molecules23092215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Knoedler S., Broichhausen S., Guo R., Dai R., Knoedler L., Kauke-Navarro M., et al. (2023). Fibroblasts - the cellular choreographers of wound healing. Front. Immunol. 14, 1233800. 10.3389/fimmu.2023.1233800 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Konda S. R., Perskin C. R., Parola R., Littlefield C. P., Egol K. A. (2021). Established trauma triage score predicts risk of falling after femoral neck fracture arthroplasty surgery. J. Healthc. Qual. 43, e91–e97. 10.1097/jhq.0000000000000311 [DOI] [PubMed] [Google Scholar]
  87. Krzyszczyk P., Schloss R., Palmer A., Berthiaume F. (2018). The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. Front. Physiol. 9, 419. 10.3389/fphys.2018.00419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Kulalert W., Wells A. C., Link V. M., Lim A. I., Bouladoux N., Nagai M., et al. (2024). The neuroimmune CGRP-RAMP1 axis tunes cutaneous adaptive immunity to the microbiota. Proc. Natl. Acad. Sci. U. S. A. 121, e2322574121. 10.1073/pnas.2322574121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Kuo L. E., Abe K., Zukowska Z. (2007). Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 28, 435–440. 10.1016/j.peptides.2006.08.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Kvich L., Burmolle M., Bjarnsholt T., Lichtenberg M. (2020). Do mixed-species biofilms dominate in chronic infections? need for in situ visualization of bacterial organization. Front. Cell Infect. Microbiol. 10, 396. 10.3389/fcimb.2020.00396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Lai W. F. (2021). Development of hydrogels with self-healing properties for delivery of bioactive agents. Mol. Pharm. 18, 1833–1841. 10.1021/acs.molpharmaceut.0c00874 [DOI] [PubMed] [Google Scholar]
  92. Landen N. X., Li D., Stahle M. (2016). Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol. Life Sci. 73, 3861–3885. 10.1007/s00018-016-2268-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Lee E. W., Michalkiewicz M., Kitlinska J., Kalezic I., Switalska H., Yoo P., et al. (2003). Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J. Clin. Invest. 111, 1853–1862. 10.1172/JCI16929 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Leal E. C., Carvalho E., Tellechea A., Kafanas A., Tecilazich F., Kearney C., et al. (2015). Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. Am. J. Pathol. 185, 1638–1648. 10.1016/j.ajpath.2015.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Lertkiatmongkol P., Liao D., Mei H., Hu Y., Newman P. J. (2016). Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol. 23, 253–259. 10.1097/MOH.0000000000000239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Li Q., Deng Z. (2008). Orthogonal-blendshape-based editing system for facial motion capture data. IEEE Comput. Graph Appl. 28, 76–82. 10.1109/MCG.2008.120 [DOI] [PubMed] [Google Scholar]
  97. Li X., Yi M., Song Z., Ni T., Tu L., Yu M., et al. (2025). A calcitonin gene-related peptide co-crosslinked hydrogel promotes diabetic wound healing by regulating M2 macrophage polarization and angiogenesis. Acta Biomater. 196, 109–122. 10.1016/j.actbio.2025.02.046 [DOI] [PubMed] [Google Scholar]
  98. Li M., Wang M., Wang H., Sun Y., Zhang Y., Xu S., et al. (2026). Ultrasound controlled-release hydrogel promotes diabetic wound healing via neuroimmune modulation and synergistic ROS scavenging. Adv. Sci. (Weinh) 13, e16882. 10.1002/advs.202516882 [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Lim J. E., Chung E., Son Y. (2017). A neuropeptide, Substance-P, directly induces tissue-repairing M2 like macrophages by activating the PI3K/Akt/mTOR pathway even in the presence of IFNgamma. Sci. Rep. 7, 9417. 10.1038/s41598-017-09639-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Lin X., Zhang X., Wang Y., Chen W., Zhu Z., Wang S. (2025). Hydrogels and hydrogel-based drug delivery systems for promoting refractory wound healing: applications and prospects. Int. J. Biol. Macromol. 285, 138098. 10.1016/j.ijbiomac.2024.138098 [DOI] [PubMed] [Google Scholar]
  101. Liu N., Li J., Lv J., Yu J., Xie J., Wu Y., et al. (2021). Melatonin alleviates imidacloprid phytotoxicity to cucumber (Cucumis sativus L.) through modulating redox homeostasis in plants and promoting its metabolism by enhancing glutathione dependent detoxification. Ecotoxicol. Environ. Saf. 217, 112248. 10.1016/j.ecoenv.2021.112248 [DOI] [PubMed] [Google Scholar]
  102. Liu M., Wei X., Zheng Z., Li Y., Li M., Lin J., et al. (2023). Recent advances in nano-drug delivery systems for the treatment of diabetic wound healing. Int. J. Nanomedicine 18, 1537–1560. 10.2147/ijn.s395438 [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Liu X., Chen J., Zou L., Lu X., Zhu B., Li J., et al. (2025). Acupuncture accelerates wound healing via CGRP-RAMP1-TSP1-mediated macrophage M2 polarization. Chin. Med. 20, 192. 10.1186/s13020-025-01255-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Lou J., Xiang Z., Zhu X., Li J., Jin G., Cui S., et al. (2025). Skin microbiota and diabetic foot ulcers. Front. Microbiol. 16, 1575081. 10.3389/fmicb.2025.1575081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Lu Y. Z., Nayer B., Singh S. K., Alshoubaki Y. K., Yuan E., Park A. J., et al. (2024). CGRP sensory neurons promote tissue healing via neutrophils and macrophages. Nature 628, 604–611. 10.1038/s41586-024-07237-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Lubics A., Reglodi D., Szelier M., Lengvári I., Kozicz T. (2003). Comparative distribution of urocortin- and CRF-like immunoreactivities in the nervous system of the earthworm Lumbricus terrestris. Peptides 24, 205–213. 10.1016/s0196-9781(03)00028-7 [DOI] [PubMed] [Google Scholar]
  107. Ma Z. J., Yang J. J., Lu Y. B., Liu Z. Y., Wang X. X. (2020). Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in regenerative medicine. World J. Stem Cells 12, 814–840. 10.4252/wjsc.v12.i8.814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Maday S., Twelvetrees A. E., Moughamian A. J., Holzbaur E. L. F. (2014). Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron 84, 292–309. 10.1016/j.neuron.2014.10.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Maggiotto F., Dalla Valle E., Fietta A., Visentin L. M., Giomo M., Cimetta E. (2025). 3D bioprinting of a perfusable skin-on-chip model suitable for drug testing and wound healing studies. Mater Today Bio 33, 101974. 10.1016/j.mtbio.2025.101974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Maranha A., Leal E. C., Alarico S., Tiago I., Pereira S. G., Empadinhas N., et al. (2026). Neuropeptides neurotensin and substance P accelerate diabetic wound healing by modulating immunity and the skin microbiome. Sci. Rep. 16, 9456. 10.1038/s41598-025-30723-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Marti-Carvajal A. J., Gluud C., Nicola S., Simancas-Racines D., Reveiz L., Oliva P., et al. (2015). Growth factors for treating diabetic foot ulcers. Cochrane Database Syst. Rev. 2015, CD008548. 10.1002/14651858.CD008548.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Mashaghi A., Marmalidou A., Tehrani M., Grace P. M., Pothoulakis C., Dana R. (2016). Neuropeptide substance P and the immune response. Cell Mol. Life Sci. 73, 4249–4264. 10.1007/s00018-016-2293-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Massad S. G., Karam R., Brown R., Glick P., Shaheen M., Linnemayr S., et al. (2014). Perceptions of sexual risk behavior among Palestinian youth in the west bank: a qualitative investigation. BMC Public Health 14, 1213. 10.1186/1471-2458-14-1213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Mathews V., George B., Lakshmi K. M., Viswabandya A., Bajel A., Balasubramanian P., et al. (2006). Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107, 2627–2632. 10.1182/blood-2005-08-3532 [DOI] [PubMed] [Google Scholar]
  115. McConalogue K., Corvera C. U., Gamp P. D., Grady E. F., Bunnett N. W. (1998). Desensitization of the neurokinin-1 receptor (NK1-R) in neurons: effects of substance P on the distribution of NK1-R, Galphaq/11, G-protein receptor kinase-2/3, and beta-arrestin-1/2. Mol. Biol. Cell 9, 2305–2324. 10.1091/mbc.9.8.2305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. McLatchie L. M., Fraser N. J., Main M. J., Wise A., Brown J., Thompson N., et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333–339. 10.1038/30666 [DOI] [PubMed] [Google Scholar]
  117. Messina A., Villa F., Cecconi M. (2022). Challenges in the hemodynamic management of acute nontraumatic neurological injuries. Curr. Opin. Crit. Care 28, 138–144. 10.1097/mcc.0000000000000925 [DOI] [PubMed] [Google Scholar]
  118. Michel M. C., Bischoff A., Jakobs K. H. (2002). Comparison of problem-and lecture-based pharmacology teaching. Trends Pharmacol. Sci. 23, 168–170. 10.1016/s0165-6147(00)01940-4 [DOI] [PubMed] [Google Scholar]
  119. Milne J., Swift A., Smith J., Martin R. (2021). Electrical stimulation for pain reduction in hard-to-heal wound healing. J. Wound Care 30, 568–580. 10.12968/jowc.2021.30.7.568 [DOI] [PubMed] [Google Scholar]
  120. Montana G., Lampiasi N. (2016). Substance P induces HO-1 expression in RAW 264.7 cells promoting switch towards M2-Like macrophages. PLoS One 11, e0167420. 10.1371/journal.pone.0167420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Moore C. A., Milano S. K., Benovic J. L. (2007). Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 69, 451–482. 10.1146/annurev.physiol.69.022405.154712 [DOI] [PubMed] [Google Scholar]
  122. Morrison A., Madden C., Messmer J. (2022). Management of chronic wounds. Prim. Care 49, 85–98. 10.1016/j.pop.2021.10.009 [DOI] [PubMed] [Google Scholar]
  123. Mostek-Majewska A., Janta A., Majewska A., Ciereszko A. (2021). Effect of 2-Cys peroxiredoxins inhibition on redox modifications of bull sperm proteins. Int. J. Mol. Sci. 22, 12888. 10.3390/ijms222312888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Muffley L. A., Zhu K. Q., Engrav L. H., Gibran N. S., Hocking A. M. (2011). Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. J. Histochem Cytochem 59, 278–288. 10.1369/0022155410397999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Mukherjee N., Ghosh S. (2023). Substance P-Derived extracellular-matrix-mimicking peptide hydrogel as a cytocompatible biomaterial platform. Chembiochem 24, e202300286. 10.1002/cbic.202300286 [DOI] [PubMed] [Google Scholar]
  126. Mulcahy L. A., Pink R. C., Carter D. R. (2014). Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3 (1), 24641. 10.3402/jev.v3.24641 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Muller M., Trocme C., Lardy B., Morel F., Halimi S., Benhamou P. Y. (2008). Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet. Med. 25, 419–426. 10.1111/j.1464-5491.2008.02414.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Murphy E. A., Davis J. M., Carmichael M. D., Gangemi J. D., Ghaffar A., Mayer E. P. (2008). Exercise stress increases susceptibility to influenza infection. Brain Behav. Immun. 22, 1152–1155. 10.1016/j.bbi.2008.06.004 [DOI] [PubMed] [Google Scholar]
  129. Muttenthaler M., King G. F., Adams D. J., Alewood P. F. (2021). Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309–325. 10.1038/s41573-020-00135-8 [DOI] [PubMed] [Google Scholar]
  130. Nardini P., Bacci S. (2025). Neuroimmunomodulation in chronic wounds: an opinion. Front. Cell Dev. Biol. 13, 1562346. 10.3389/fcell.2025.1562346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Nguyen T., Marusich J., Li J. X., Zhang Y. (2020). Neuropeptide FF and its receptors: therapeutic applications and ligand development. J. Med. Chem. 63, 12387–12402. 10.1021/acs.jmedchem.0c00643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Nie A. A., Taylor B. K. (2025). The pharmacotherapeutic potential of neuropeptide Y for chronic pain. J. Intern Med. 298, 280–296. 10.1111/joim.20118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Nikas I., McLauchlan J., Davison A. J., Taylor W. R., Clements J. B. (1986). Structural features of ribonucleotide reductase. Proteins 1, 376–384. 10.1002/prot.340010411 [DOI] [PubMed] [Google Scholar]
  134. Nishimoto M., Miyakawa H., Wada K., Furuta A. (2011). Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Brain Res. 1383, 43–53. 10.1016/j.brainres.2011.01.082 [DOI] [PubMed] [Google Scholar]
  135. Nowak N. C., Menichella D. M., Miller R., Paller A. S. (2021). Cutaneous innervation in impaired diabetic wound healing. Transl. Res. 236, 87–108. 10.1016/j.trsl.2021.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Olias G., Viollet C., Kusserow H., Epelbaum J., Meyerhof W. (2004). Regulation and function of somatostatin receptors. J. Neurochem. 89, 1057–1091. 10.1111/j.1471-4159.2004.02402.x [DOI] [PubMed] [Google Scholar]
  137. Oliveira J. T., Yanick C., Wein N., Gomez Limia C. E. (2023). Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment. Front. Cell Neurosci. 17, 1248922. 10.3389/fncel.2023.1248922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Paillusson S., Stoica R., Gomez-Suaga P., Lau D. H. W., Mueller S., Miller T., et al. (2016). There's something wrong with my MAM; the ER-Mitochondria axis and neurodegenerative diseases. Trends Neurosci. 39, 146–157. 10.1016/j.tins.2016.01.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Palazzo E., Marconi A., Truzzi F., Dallaglio K., Petrachi T., Humbert P., et al. (2012). Role of neurotrophins on dermal fibroblast survival and differentiation. J. Cell Physiol. 227, 1017–1025. 10.1002/jcp.22811 [DOI] [PubMed] [Google Scholar]
  140. Palomeque Chavez J. C., Dobricic M., McGrath M., O'Connor C., McGuire T., Maughan J., et al. (2026). Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing. Bioact. Mater 61, 373–390. 10.1016/j.bioactmat.2026.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Park J. H., Kim S., Hong H. S., Son Y. (2016). Substance P promotes diabetic wound healing by modulating inflammation and restoring cellular activity of mesenchymal stem cells. Wound Repair Regen. 24, 337–348. 10.1111/wrr.12413 [DOI] [PubMed] [Google Scholar]
  142. Pastar I., Balukoff N. C., Marjanovic J., Chen V. Y., Stone R. C., Tomic-Canic M. (2023). Molecular pathophysiology of chronic wounds: current state and future directions. Cold Spring Harb. Perspect. Biol. 15, a041243. 10.1101/cshperspect.a041243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Patel H. K., Bihani T. (2018). Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther. 186, 1–24. 10.1016/j.pharmthera.2017.12.012 [DOI] [PubMed] [Google Scholar]
  144. Pereira M. R., Leite P. E. (2016). The involvement of parasympathetic and sympathetic nerve in the inflammatory reflex. J. Cell Physiol. 231, 1862–1869. 10.1002/jcp.25307 [DOI] [PubMed] [Google Scholar]
  145. Pollock K., Liu M., Zaleska M., Meniconi M., Pfuhl M., Collins I., et al. (2019). Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase. Sci. Rep. 9, 19130. 10.1038/s41598-019-55240-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Powers J. G., Higham C., Broussard K., Phillips T. J. (2016). Wound healing and treating wounds: chronic wound care and management. J. Am. Acad. Dermatol 74, 607–625. 10.1016/j.jaad.2015.08.070 [DOI] [PubMed] [Google Scholar]
  147. Pradhan L., Nabzdyk C., Andersen N. D., LoGerfo F. W., Veves A. (2009). Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev. Mol. Med. 11, e2. 10.1017/S1462399409000945 [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Profumo E., Maggi E., Arese M., Di Cristofano C., Salvati B., Saso L., et al. (2022). Neuropeptide Y promotes human M2 macrophage polarization and enhances p62/SQSTM1-Dependent autophagy and NRF2 activation. Int. J. Mol. Sci. 23, 13009. 10.3390/ijms232113009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Raffetto J. D., Ligi D., Maniscalco R., Khalil R. A., Mannello F. (2020). Why venous leg ulcers have difficulty healing: overview on pathophysiology, clinical consequences, and treatment. J. Clin. Med. 10, 29. 10.3390/jcm10010029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Raziyeva K., Kim Y., Zharkinbekov Z., Kassymbek K., Jimi S., Saparov A. (2021). Immunology of Acute and chronic wound healing. Biomolecules 11, 700. 10.3390/biom11050700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Redkiewicz P. (2022). The regenerative potential of substance P. Int. J. Mol. Sci. 23, 750. 10.3390/ijms23020750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Rodrigues M., Kosaric N., Bonham C. A., Gurtner G. C. (2019). Wound healing: a cellular perspective. Physiol. Rev. 99, 665–706. 10.1152/physrev.00067.2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Roosterman D., Goerge T., Schneider S. W., Bunnett N. W., Steinhoff M. (2006). Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol. Rev. 86, 1309–1379. 10.1152/physrev.00026.2005 [DOI] [PubMed] [Google Scholar]
  154. Rozanova J., Miller E. A., Wetle T. (2016). Depictions of nursing home residents in US newspapers: successful ageing versus frailty. Aging Soc. 36, 17–41. 10.1017/S0144686X14000907 [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Russell F. A., King R., Smillie S. J., Kodji X., Brain S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94, 1099–1142. 10.1152/physrev.00034.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Salles J., Ponte C., Schmitt L. (2019). Psychotic decompensation during nalmefene treatment in a patient with schizoaffective disorder: a case report. J. Dual Diagn 15, 118–121. 10.1080/15504263.2019.1574367 [DOI] [PubMed] [Google Scholar]
  157. Sango K., Mizukami H., Horie H., Yagihashi S. (2017). Impaired axonal regeneration in diabetes. Perspective on the underlying mechanism from in vivo and in vitro experimental studies. Front. Endocrinol. (Lausanne) 8, 12. 10.3389/fendo.2017.00012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Sato H., Ebisawa K., Takanari K., Yagi S., Toriyama K., Yamawaki-Ogata A., et al. (2015). Skin-derived precursor cells promote wound healing in diabetic mice. Ann. Plast. Surg. 74, 114–120. 10.1097/SAP.0000000000000342 [DOI] [PubMed] [Google Scholar]
  159. Schroeder K. M., Agazio A., Torres R. M. (2017). Immunological tolerance as a barrier to protective HIV humoral immunity. Curr. Opin. Immunol. 47, 26–34. 10.1016/j.coi.2017.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Sebastian A., Syed F., Perry D., Balamurugan V., Colthurst J., Chaudhry I. H., et al. (2011). Acceleration of cutaneous healing by electrical stimulation: degenerate electrical waveform down-regulates inflammation, up-regulates angiogenesis and advances remodeling in temporal punch biopsies in a human volunteer study. Wound Repair Regen. 19, 693–708. 10.1111/j.1524-475X.2011.00736.x [DOI] [PubMed] [Google Scholar]
  161. Shu B., Xie J. L., Xu Y. B., Lai W., Huang Y., Mao R. X., et al. (2015). Effects of skin-derived precursors on wound healing of denervated skin in a nude mouse model. Int. J. Clin. Exp. Pathol. 8, 2660–2669. [PMC free article] [PubMed] [Google Scholar]
  162. Sigorski D., Sejda A., Abualsaud N., Krawczyk E., Izycka-Swieszewska E., Kitlinska J. (2025). Neuropeptide Y in cancer-biological functions and potential clinical implications. Cancer Metastasis Rev. 44, 21. 10.1007/s10555-024-10237-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Singer K., Morris D. L., Oatmen K. E., Wang T., DelProposto J., Mergian T., et al. (2013). Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PLoS One 8, e57929. 10.1371/journal.pone.0057929 [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Singla S., Dempsey C., Warren R., Enikolopov A. G., Sawtell N. B. (2017). A cerebellum-like circuit in the auditory system cancels responses to self-generated sounds. Nat. Neurosci. 20, 943–950. 10.1038/nn.4567 [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Smiell J. M., Wieman T. J., Steed D. L., Perry B. H., Sampson A. R., Schwab B. H. (1999). Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 7, 335–346. 10.1046/j.1524-475x.1999.00335.x [DOI] [PubMed] [Google Scholar]
  166. Song H., Xu Y., Chang W., Zhuang J., Wu X. (2020). Negative pressure wound therapy promotes wound healing by suppressing macrophage inflammation in diabetic ulcers. Regen. Med. 15, 2341–2349. 10.2217/rme-2020-0050 [DOI] [PubMed] [Google Scholar]
  167. Stangerup T., Gjerdrum L. M. R., Bzorek M., Andersen L., Heegaard A. M., Jorgensen L. N., et al. (2024). Topical neuropeptide Y for ischemic skin wounds. Int. J. Mol. Sci. 25, 3346. 10.3390/ijms25063346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Stanojevic S., Wade A., Cole T. J., Lum S., Custovic A., Silverman M., et al. (2009). Spirometry centile charts for young Caucasian children: the Asthma UK collaborative initiative. Am. J. Respir. Crit. Care Med. 180, 547–552. 10.1164/rccm.200903-0323oc [DOI] [PubMed] [Google Scholar]
  169. Steinhoff M. S., von Mentzer B., Geppetti P., Pothoulakis C., Bunnett N. W. (2014). Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev. 94, 265–301. 10.1152/physrev.00031.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Suvas S. (2017). Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J. Immunol. 199, 1543–1552. 10.4049/jimmunol.1601751 [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Tanaka M., Szabo A., Kortesi T., Szok D., Tajti J., Vécsei L. (2023). From CGRP to PACAP, VIP, and beyond: unraveling the next chapters in migraine treatment. Cells 12, 2649. 10.3390/cells12222649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Tao S. C., Guo S. C., Li M., Ke Q. F., Guo Y. P., Zhang C. Q. (2017). Chitosan wound dressings incorporating exosomes derived from MicroRNA-126-Overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model. Stem Cells Transl. Med. 6, 736–747. 10.5966/sctm.2016-0275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Tasdemiroglu Y., Gourdie R. G., He J. Q. (2022). In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases. Eur. J. Pharmacol. 932, 175192. 10.1016/j.ejphar.2022.175192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Theocharidis G., Veves A. (2020). Autonomic nerve dysfunction and impaired diabetic wound healing: the role of neuropeptides. Auton. Neurosci. 223, 102610. 10.1016/j.autneu.2019.102610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Theocharidis G., Thomas B. E., Sarkar D., Mumme H. L., Pilcher W. J. R., Dwivedi B., et al. (2022). Single cell transcriptomic landscape of diabetic foot ulcers. Nat. Commun. 13, 181. 10.1038/s41467-021-27801-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Toma J. G., McKenzie I. A., Bagli D., Miller F. D. (2005). Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 23, 727–737. 10.1634/stemcells.2004-0134 [DOI] [PubMed] [Google Scholar]
  177. Toth D., Szabo E., Tamas A., Juhasz T., Horvath G., Fabian E., et al. (2020). Protective effects of PACAP in peripheral organs. Front. Endocrinol. (Lausanne) 11, 377. 10.3389/fendo.2020.00377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Turner J. G., White L. R., Estrela P., Leese H. S. (2021). Hydrogel-forming microneedles: current advancements and future trends. Macromol. Biosci. 21, e2000307. 10.1002/mabi.202000307 [DOI] [PubMed] [Google Scholar]
  179. Um J., Jung N., Chin S., Cho Y., Choi S., Park K. S. (2016). Substance P enhances EPC mobilization for accelerated wound healing. Wound Repair Regen. 24, 402–410. 10.1111/wrr.12403 [DOI] [PubMed] [Google Scholar]
  180. Verdes M., Mace K., Margetts L., Cartmell S. (2022). Status and challenges of electrical stimulation use in chronic wound healing. Curr. Opin. Biotechnol. 75, 102710. 10.1016/j.copbio.2022.102710 [DOI] [PubMed] [Google Scholar]
  181. Versey Z., da Cruz Nizer W. S., Russell E., Zigic S., DeZeeuw K. G., Marek J. E., et al. (2021). Biofilm-innate immune interface: contribution to chronic wound formation. Front. Immunol. 12, 648554. 10.3389/fimmu.2021.648554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Viero C., Shibuya I., Kitamura N., Verkhratsky A., Fujihara H., Katoh A., et al. (2010). REVIEW: oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neurosci. Ther. 16, e138–e156. 10.1111/j.1755-5949.2010.00185.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Vishnivetskiy S. A., Schubert C., Climaco G. C., Gurevich Y. V., Velez M. G., Gurevich V. V. (2000). An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation. J. Biol. Chem. 275, 41049–41057. 10.1074/jbc.M007159200 [DOI] [PubMed] [Google Scholar]
  184. Wahlestedt C., Yanaihara N., Hakanson R. (1986). Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept. 13, 307–318. 10.1016/0167-0115(86)90048-0 [DOI] [PubMed] [Google Scholar]
  185. Wang Y., Chen Z., Luo G., He W., Xu K., Xu R., et al. (2016). In-situ-generated vasoactive intestinal peptide loaded microspheres in mussel-inspired polycaprolactone nanosheets creating spatiotemporal releasing microenvironment to promote wound healing and angiogenesis. ACS Appl. Mater Interfaces 8, 7411–7421. 10.1021/acsami.5b11332 [DOI] [PubMed] [Google Scholar]
  186. Wang L., Wang N., Zhang W., Cheng X., Yan Z., Shao G., et al. (2022). Therapeutic peptides: current applications and future directions. Signal Transduct. Target Ther. 7, 48. 10.1038/s41392-022-00904-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Wang X., Wu J., Wang M., Lu C., Li W., Lu Q., et al. (2023). Substance P&dimethyloxallyl glycine-loaded carboxymethyl chitosan/gelatin hydrogel for wound healing. J. Biomed. Mater Res. A 111, 404–414. 10.1002/jbm.a.37475 [DOI] [PubMed] [Google Scholar]
  188. Wang J., Yang X., Zhou T., Ma H., Yuan X., Yan S., et al. (2025a). Microenvironment of diabetic foot ulcers: implications for healing and therapeutic strategies. J. Res. Med. Sci. 30, 19. 10.4103/jrms.jrms_573_24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Wang Q., Liu C., An J., Liu J., Wang Y., Cai Y. (2025b). Mechanisms of microbial infection and wound healing in diabetic foot ulcer: pathogenicity in the inflammatory-proliferative phase, chronicity, and treatment strategies. Front. Endocrinol. (Lausanne) 16, 1657928. 10.3389/fendo.2025.1657928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Wang H., Yang L., Jiang H., Li Z., Zhou X., Wang B., et al. (2026). Skin-mimetic bilayer hydrogel enhances spatiotemporal coordination of neuro-immune-vascular interactions to accelerate diabetic wound healing. Bioact. Mater 61, 758–773. 10.1016/j.bioactmat.2026.02.054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Wee L. Y., Taylor M. J., Talbert D., Fisk N. M. (2003). Variable umbilical artery end-diastolic frequency is associated with arterio-arterial anastomosis. Ultrasound Obstet. Gynecol. 21, 626. 10.1002/uog.175 [DOI] [PubMed] [Google Scholar]
  192. Wei Z., Xie Y., Wei M., Zhao H., Ren K., Feng Q., et al. (2022). New insights in ferroptosis: potential therapeutic targets for the treatment of ischemic stroke. Front. Pharmacol. 13, 1020918. 10.3389/fphar.2022.1020918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  193. Welsh J. A., Goberdhan D. C. I., O'Driscoll L., Buzas E. I., Blenkiron C., Bussolati B., et al. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J. Extracell. Vesicles 13, e12404. 10.1002/jev2.12404 [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Wen P., Tiwari P., Mauthe S., Schmid H., Sousa M., Scherrer M., et al. (2022). Waveguide coupled III-V photodiodes monolithically integrated on Si. Nat. Commun. 13, 909. 10.1038/s41467-022-28502-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Wijesinghe A., Kumari S., Booth V. (2022). Conjugates for use in peptide therapeutics: a systematic review and meta-analysis. PLoS One 17, e0255753. 10.1371/journal.pone.0255753 [DOI] [PMC free article] [PubMed] [Google Scholar]
  196. Wilkinson H. N., Hardman M. J. (2020). Wound healing: cellular mechanisms and pathological outcomes. Open Biol. 10, 200223. 10.1098/rsob.200223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Willer A., Heinzmann U., Mellert W., Kleinschmidt A., Goebel F. D., Erfle V. (1993). Reduction of HIV-1 antigen production by phosphatidylcholine containing formulations via growth inhibition of HIV-1-infected cells. Res. Exp. Med. Berl. 193, 123–135. 10.1007/BF02576219 [DOI] [PubMed] [Google Scholar]
  198. Wultsch T., Painsipp E., Donner S., Sperk G., Herzog H., Peskar B. A., et al. (2006). Selective increase of dark phase water intake in neuropeptide-Y Y2 and Y4 receptor knockout mice. Behav. Brain Res. 168, 255–260. 10.1016/j.bbr.2005.11.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Xia Y., Wu P., Chen Y., Chen Z. (2025). Current research progress on the use of traditional Chinese medicine in the treatment of diabetic foot ulcers. Front. Endocrinol. (Lausanne) 16, 1637128. 10.3389/fendo.2025.1637128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Xiao W., Jiang W., Chen Z., Huang Y., Mao J., Zheng W., et al. (2025). Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct. Target Ther. 10, 74. 10.1038/s41392-024-02107-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Xing Y., Sun X., Dou Y., Wang M., Zhao Y., Yang Q., et al. (2021). The immuno-modulation effect of macrophage-derived extracellular vesicles in chronic inflammatory diseases. Front. Immunol. 12, 785728. 10.3389/fimmu.2021.785728 [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Xing L., Chen B., Qin Y., Li X., Zhou S., Yuan K., et al. (2024). The role of neuropeptides in cutaneous wound healing: a focus on mechanisms and neuropeptide-derived treatments. Front. Bioeng. Biotechnol. 12, 1494865. 10.3389/fbioe.2024.1494865 [DOI] [PMC free article] [PubMed] [Google Scholar]
  203. Xu M., Su X., Xiao X., Yu H., Li X., Keating A., et al. (2021). Hydrogen peroxide-induced senescence reduces the wound healing-promoting effects of mesenchymal stem cell-derived exosomes partially via miR-146a. Aging Dis. 12, 102–115. 10.14336/ad.2020.0624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  204. Xu Y., Hu Q., Wei Z., Ou Y., Cao Y., Zhou H., et al. (2023). Advanced polymer hydrogels that promote diabetic ulcer healing: mechanisms, classifications, and medical applications. Biomater. Res. 27, 36. 10.1186/s40824-023-00379-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  205. Yang B., Gomes Dos Santos A., Puri S., Bak A., Zhou L. (2022). The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opin. Drug Deliv. 19, 1233–1245. 10.1080/17425247.2022.2098276 [DOI] [PubMed] [Google Scholar]
  206. Yu X. J., Ren X. H., Xu Y. H., Chen L. M., Zhou C. L., Li C. Y. (2010). Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway. Neuropeptides 44, 407–411. 10.1016/j.npep.2010.05.002 [DOI] [PubMed] [Google Scholar]
  207. Yuan M., Liu Y., Peng X., Li Z., Lei M. (2026). Chronic wound healing: research advances from pathological mechanisms to natural herbal active ingredients and material delivery systems. Molecules 31, 1024. 10.3390/molecules31061024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  208. Zaarour R. F., Saha D., Dey R., Dutta A., Kumar P., Rana I., et al. (2022). The neuropeptide substance P facilitates the transition from an inflammatory to proliferation phase-associated responses in dermal fibroblasts. Exp. Dermatol 31, 1188–1201. 10.1111/exd.14573 [DOI] [PubMed] [Google Scholar]
  209. Zamani S., Ehterami A., Vaez A., Naeiji M., Maghsoodifar H., Sadeghi douki S. A. H., et al. (2026). Natural and synthetic polymers in burn wound healing. J. Biomater. Sci. Polym. Ed. 37, 118–183. 10.1080/09205063.2025.2523505 [DOI] [PubMed] [Google Scholar]
  210. Zhang J., Ferre-D'Amare A. R. (2014). Dramatic improvement of crystals of large RNAs by cation replacement and dehydration. Structure 22, 1363–1371. 10.1016/j.str.2014.07.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Zhang W., Bai X., Zhao B., Li Y., Zhang Y., Li Z., et al. (2018). Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp. Cell Res. 370, 333–342. 10.1016/j.yexcr.2018.06.035 [DOI] [PubMed] [Google Scholar]
  212. Zhang Y., Liu C. Y., Chen W. C., Shi Y. C., Wang C. M., Lin S., et al. (2021). Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review. Cell Biosci. 11, 151. 10.1186/s13578-021-00657-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Zhang J., He Z., Xiong C., Yao Y., Zhang C., Yao W., et al. (2024). SHH induces macrophage oxidative phosphorylation and efferocytosis to promote scar formation. Cell Commun. Signal 22, 336. 10.1186/s12964-024-01692-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Zhao Y., Huang L., Sumampouw F., Ren Z., An X., Du H., et al. (2026). Sustained-release CGRP microspheres accelerate diabetic wound healing by synergistically promoting neurovascular regeneration through modulation of macrophage and endothelial cell functions. Mater Today Bio 37, 103015. 10.1016/j.mtbio.2026.103015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  215. Zhu Y., Yao Z., Liu Y., Zhang W., Geng L., Ni T. (2020). Incorporation of ROS-responsive substance P-Loaded zeolite imidazolate Framework-8 nanoparticles into a Ca(2+)-Cross-Linked alginate/pectin hydrogel for wound dressing applications. Int. J. Nanomedicine 15, 333–346. 10.2147/IJN.S225197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Zhu S., Yu Y., Ren Y., Xu L., Wang H., Ling X., et al. (2021). The emerging roles of neutrophil extracellular traps in wound healing. Cell Death Dis. 12, 984. 10.1038/s41419-021-04294-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Zhu D., Li Y., Zhao L., Pei D., Guo Y., Liu L. (2025). SQSTM1/p62 post-translational modifications and reverse processes modulate disease pathogenesis via KEAP1-NRF2 signaling and selective autophagy. Antioxid. Redox Signal 43, 745–764. 10.1177/15230864251395963 [DOI] [PubMed] [Google Scholar]
  218. Ziche M., Morbidelli L., Pacini M., Dolara P., Maggi C. A. (1990). NK1-receptors mediate the proliferative response of human fibroblasts to tachykinins. Br. J. Pharmacol. 100, 11–14. 10.1111/j.1476-5381.1990.tb12043.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Zieglgansberger W. (2019). Substance P and pain chronicity. Cell Tissue Res. 375, 227–241. 10.1007/s00441-018-2922-y [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Cell and Developmental Biology are provided here courtesy of Frontiers Media SA

RESOURCES